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CHAPTER I 
 
Introduction 
 
 
CD4+ Effector T cell Lineages, Properties, and Functions 
 
 
Cellular Immunity and CD4+ Th Effector Phenotypes 
 
Immune surveillance permits a host to identify and sequester invading pathogens 
or foreign materials. Defense against a spectrum of pathogenic microbial 
infections requires the activity of a diverse repertoire of immune cells, which can 
be broadly divided into innate and adaptive components.  Innate immune cells 
directly sense and ingest pathogens and produce pro-inflammatory cytokines and 
antimicrobial agents, including TNF-α, IL-1, IL-6, nitric oxide (NO), antimicrobial 
peptides, and reactive oxygen species (ROS). Innate immune cells respond to 
conserved pathogen-associated molecular patterns expressed on the surface of 
bacteria and create a hostile environment for infection, either by production of 
proinflammatory cytokines or chemokines that recruit more inflammatory cells. 
Innate immune cells include myeloid cells, including monocytes, macrophages, 
granulocytes, and dendritic cells, as well as innate lymphoid cells. In contrast to 
the non-specific innate response that recognizes non-specific pathogens,
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adaptive immunity results in an antigen-specific response and the formation of 
memory, allowing a long-lasting, highly efficient response to subsequent 
infection. Adaptive immune cells include T lymphocytes (CD4+ and CD8+ cells) 
and B lymphocytes, which express unique antigen recognition receptors on their 
cell surface. The receptor expressed on T cells is referred to as the T cell 
receptor (TCR). Ideally, the TCR is specific to peptides unique to foreign 
pathogens presented by APCs in the context of a major histocompatibility 
complex (MHC) molecule. Briefly, APCs phagocytose pathogens or their 
components, process them internally to form a peptide-MHC complex, and 
present the complex on the APC surface.  A T cell expressing a unique TCR that 
recognizes that particular peptide interacts with the peptide MHC complex as well 
as costimulation molecules expressed by the activated APC to activate the T cell 
itself. Activated T cells produce effector cytokines and chemokines to promote 
inflammatory cell activation and recruitsment to the site of infection. CD8+ T cell 
TCRs are triggered by peptides that are complexed with MHC Class I (MHC I) 
molecules, which are expressed by all cells other than erythrocytes. CD8+ T cells 
directly kill cells that present cognate antigen in the context of MHC I. CD4+ T 
cells are triggered by peptides complexed with MHC Class II molecules, which 
are exclusively expressed by “professional” APCs, and include dendritic cells, 
macrophages, and B cells. CD4+ T cells are considered T helper cells (Th), as 
they function as potent innate immune cell activators and contribute to B cell 
maturation and antibody class switching.  
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Ligation of the TCR with the peptide-MHC complex, in combination with co-
stimulatory molecule interactions and cytokines expressed by APCs, expands 
and differentiates naïve T cells along different lineages toward the formation of 
effector and memory cells. While effector cells produce high levels of 
proinflammatory cytokines at the site of infection, CD4+ and CD8+ memory T 
cells have a lower threshold for activation than naïve cells and are poised to 
expand rapidly and execute effector functions upon re-encounter with cognate 
antigen. Antigen-experienced memory T cells can be divided into effector 
memory and central memory based on their cytokine function and expression of 
activation and homing molecules on their surface. Central memory T cells reside 
in secondary lymphoid tissues, produce low amounts of cytokines, and proliferate 
following antigen exposure. Conversely, effector memory cells, which may 
develop from central memory cells, are found in non-lymphoid tissue, produce 
large amounts of pro-inflammatory effector cytokines, and proliferate poorly. Both 
memory T cell populations within CD4+ and CD8+ lineages require less co-
stimulation from APCs and innate cytokines, and thereby, induce a more rapid 
and effective memory response upon subsequent exposure to the previously 
encountered antigen [1]. Following reactivation, T cells rapidly produce cytokines 
with pleiotropic effects that are best-suited for the defense against a particular 
pathogen, including induction of chemokines and adhesion molecules and 
stimulation of myeloid cells. CD4+ T cells differentiate into functionally distinct 
subsets that dictate the nature of that inflammatory response. 
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CD4+ Th lineages 
T cell polarization is driven by cytokines produced by activated innate and B cells 
[2]. APCs respond to different types of stimuli via receptors that recognize 
particular pathogen-associated molecular patterns, including the bacterial surface 
protein lipopolysaccharide and virally associated double-stranded RNA. The 
cytokines produced by the APCs and other innate cells create an environment 
that, when encountered by activated CD4+ T cell, can promote T cell polarization 
toward effector function. Divergence toward separate CD4+ T cell populations 
leads to highly effective and specific pathogen clearance following activation and 
rechallenge. CD4+ T cell lineages are characterized by the cytokines required for 
their polarization, the transcription factors that coordinate their development and 
function, their hallmark effector cytokines produced, and the environment that 
results from their activity.  
 
Th1 and Th2 cells 
Mossman and Coffman originally described two unique CD4+ populations as T 
helper 1 (Th1) and Th2 [3]. Th1 cells are marked by their expression of IFN-γ, 
while Th2 cells express IL-4, IL-5, and IL-13. Following clonal expansion, Th1 
and Th2 cells maintain hallmark cytokine production upon rechallenge long-term, 
demonstrating that they are divergent and stable lineages. Th1 cells develop 
following exposure to IFN-γ and IL-12p70 (IL-12), which are expressed by innate 
cells in response to specific pathogen-associated molecular patterns, such as 
extracellular bacteria [4].  IL-12 is produced by macrophages and dendritic cells 
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and is a heterodimer made of the IL-12p35 and IL-12p40 subunits. IL-12 signals 
through the IL-12 receptor (IL-12R), a heterodimer formed by IL-12Rβ1 and IL-
12Rβ2 [5]. IL-12R is expressed following IFN-γ receptor engagement on CD4+ T 
cells in combination with TCR stimulation with antigen complexed with MHCII 
and co-stimulatory molecule interactions [6]. Signaling via the IFN-γ receptor 
promotes the activity of T-bet, a transcription factor considered to be the “master” 
transcription factor for Th1 cells directly regulating the expression of IL-12Rβ2 [4, 
7, 8].  IL-12R engagement promotes the phosphorylation of signal transducer 
and activator of transcription (STAT) 1 and STAT4 to further enhance the Th1 
program [9]. IFN-γ then acts as the defining cytokine and effector molecule for 
Th1 and functions to activate macrophages, monocytes, and other inflammatory 
cells to promote phagocytosis, lysosomal degradation, oxidative species 
production, and pathogen clearance.  
 
Th2 cells, on the other hand, are defined by IL-4 production and are polarized 
following exposure to IL-4 and antigen presentation by basophils as well as other 
APCs. Th2 cells express the transcription factor GATA3 to promote their 
transcriptional program. The signature cytokine expressed by Th2 cells is IL-4.  
[10-14].  
 
Following the description of Th1 and Th2 cells, studies comparing the two cell 
types determined that different effector CD4+ T cell lineages were more or less 
effective at responding to certain antigens, owing to the cytokine milieu produced 
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following antigen encounter. For example, Leishmania major infection is 
controlled by Th1 cells in an IFN-γ-dependent manner. Mouse strains such as 
C57BL/6, which naturally mount a robust Th1 response, are able to clear and 
survive L. major infection. Other strains, such as BALB/c, have a bias toward Th2 
differentiation, cannot properly clear the infection and thus are susceptible to 
disease [15, 16]. Conversely, parasites including helminths are known to 
stimulate Th2 responses and require IL- 4 production by CD4+ T cells for their 
clearance. Th2 cells and their signature cytokines have also been found in 
allergic and atopic settings. These studies and others established a paradigm 
whereby divergent and stable CD4+ T cell subsets, defined by their polarizing 
environments, transcriptional programs, and effector cytokine production mediate 
immune responses to clear specific types of pathogens.  
 
Th17 Cells 
More recently, several other Th lineages have been described. The most 
comprehensively understood pro-inflammatory CD4+ T cell subset outside of the 
Th1/Th2 lineages is T helper 17 (Th17) cells, named for their expression of IL-
17A and other IL-17 isoforms [17, 18]. IL-17 binds to its receptor on inflammatory 
cells like neutrophils to promote their activation and recruitment. Th17 
development is promoted by IL-6, TGF-β, IL-21, IL-1, and IL-23, which are 
produced by innate cells following exposure to microbes including extracellular 
bacteria. IL-23 is similar to IL-12 in that both cytokines share the IL-12p40-/-
subunit. IL-23 however expresses a unique IL-23p19 subunit. Control of IL-23p19 
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and IL-12p35 are tightly controlled at the transcriptional level to ensure proper 
activation of either Th17 or Th1 cells, respectively. The transcriptional program of 
Th17 cells is coordinated by STAT3 phosphorylation and ROR-γt, the key 
regulator of the Th17 transcription. ROR-γt promotes the expression of IL-17, 
which then promotes recruitment and activation of innate proinflammatory cells 
and expression of other cytokines, chemokines, and antimicrobial factors [19-21]. 
Due to its effectiveness at regulating extracellular bacterial infections, Th17-
mediated immunity has been shown to be critical at mucosal and barrier sites 
[23]. 
 
Other T cell Populations 
Regulation of the inflammatory and immune response following infection is 
crucial for preventing collateral damage to the host. Moreover, the regulatory 
response is required for suppression of autoimmunity. CD4+ regulatory T cells 
(Tregs) are found systemically and can be rapidly recruited to sites of infection. 
The exact mechanism of Tregs is unclear; however they are known to suppress 
proliferation and cytokine production of activated CD4+ Th cells. Tregs produce 
IL-10 and other soluble factors to promote a suppressive environment in certain 
settings and express surface molecules, such as CTLA-4, to regulate the 
activation of APCs [24]. Treg transctiption is considered to be controlled by the 
transcription factor FoxP3 and Tregs express no Th1, Th2, or Th17 hallmark 
cytokines, nor IL-2.   
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Several other types of CD4+ T cell populations have been described, but are less 
defined or outside of the scope of this dissertation. These include Th9 cells, 
which are found in settings of parasitic helminth infection. Additionally, T follicular 
helper cells (Tfh) promote antibody production within B cell follicles. Tfh cells 
express IL-21, but most importantly they function to support B cells by providing 
T cell help at germinal centers, allowing for proper B cell activation, maturation, 
and antibody-mediated immune function [24]. 
 
Classification of different CD4+ effector populations into distinct lineages is 
convenient for determining factors that effectively mediate the immune response 
against various pathogens. However, recent data has demonstrated that in 
certain environments, T cells become unstable and acquire functions associated 
with other lineages. 
 
CD4 Th Plasticity 
 
A feature of several of the Th lineages that lie outside of the classic Th1/Th2 
paradigm is the relatively newly described feature of plasticity, particularly in the 
Th17 subset. Th17 cells have been shown to down regulate IL-17 and begin to 
exhibit properties of other Th lineages, including Th1 and Tfh cells, while Th1 and 
Th2 cells are typically considered to be stable and maintain their signature 
cytokine and transcriptional program [25]. This is perhaps due in part to 
epigenetic regulation of histone modification signatures in critical Th lineage 
genes. Wei et al. demonstrated that in Th17 cells, the loci encoding Th17-
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associated genes like rorc and il17 are poised in a “permissive” histone 
methylation state, with histone 3H trimethylated at lysine 4 (H3K4me3), which 
allows DNA to become less tightly bound to the nucleosome and promotes gene 
expression [26]. Similarly, in Th1 cells, the tbx21 and ifng loci, which encode the 
Th1 factors T-bet and IFN-γ, respectively, include permissive H3K4me3 
signatures. However, in Th17 cells, histone modifications at the tbx21 and other 
lineage-associated loci are “bivalent,” or contain both repressive H3 
trimethylation at lysine 27 (H3K27me3), as well as activating H3K4me3 
modifications. This is thought to contribute to the plasticity seen in Th17 cells, 
since Th1 and Th2 cells demonstrate fewer bivalent histone modification 
signatures at their associated loci, possibly allowing for their stability [26].  
Th17 plasticity was first demonstrated in vitro using populations of highly 
polarized IL-17-producing T cells. Following a primary stimulation in the presence 
of TGF-β and IL-6, Th17 cells rechallenged in the presence of IL-23 or IL-12 
downregulated IL-17 and upregulated IFN-γ at the population level [27]. This was 
shown to be T-bet- and STAT4-dependent. Furthermore, transfer of Th17-
polarized cells resulted in the accumulation of IFN-γ- producing T cells at sites of 
inflammation in a colitis model [27]. Other groups have demonstrated Th17 
plasticity in vivo in the context of tumor and diabetes models [28]. In 2011, Hirota 
et al. developed a fate mapping IL-17A reporter mouse to track the fate of cells 
that at any time expressed IL-17. They demonstrated that CD4+ T cells that 
expressed IL-17A could down regulate IL-17 and up regulate IFN-γ in vivo [29]. 
These cells were termed “exTh17”. Indeed, at sites of inflammation, a high 
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frequency of IFN-γ-producing CD4+ T cells, originally thought to be Th1 cells 
based on signature cytokine production, were determined to be exTh17 cells. 
The development of exTh17 cells was attributed to their T-bet expression and 
was dependent on IL-23 signaling [29].  
 
These observations raised the following questions: first, is the conversion of a 
Th17 cell to an exTh17 critical (or detrimental) for Th17-mediated immunity; and 
second, can IFN-γ-producing Th1 cells can promote inflammation independently 
of initial Th17 programming? More recent studies determined using IL-17A fate-
mapping reporter mice that Th17 cells are not only capable of becoming IFN-γ 
producers, but can also develop a Tfh-like phenotype in the Peyer’s patches and 
are critical for IgA responses in the gut [30]. Several other examples of CD4 
plasticity have been described, including in Treg and Tfh lineages, though the 
function and relevance of those cells is somewhat controversial [31-36].  In any 
case, the observation that a CD4+ effector cell lineage can convert into another 
brings into question the contribution of either cell type separately. 
 
 
CD4+ T Cells in Autoimmune Disease 
 
CD4+ T cells and other adaptive immune cells are obviously critical for clearance 
of foreign pathogens, but they can become pathogenic in the setting of 
autoimmunity. Typically, during the process of negative selection in the thymus, 
CD4+ T cells with receptors that recognize host-derived (self) antigens are 
identified and eliminated. However, many individuals have auto-reactive T cells 
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that escape the thymus. If self-reactive cells are allowed to escape, they either 
remain ignorant to their self-antigens or are tightly regulated by Tregs and other 
suppressive mechanisms that induce tolerance. However, if these regulatory 
mechanisms fail, or if self-antigens are presented in the context of danger, 
autoimmunity can occur [37]. During T cell-mediated autoimmunity, self-reactive 
T cells see their cognate auto-antigen presented by MHC molecules and mediate 
a proinflammatory immune response mediated by macrophages, DCs, and other 
cells that results in immune complex formation, tissue damage, and illness. 
Autoimmune diseases can be systemic, as in the case of systemic lupus 
erythematosus, in which antibodies specific for widespread antigens from DNA 
and nucleoproteins induce disease. Autoimmune disease can also be tissue-
specific and target a single organ or tissue-type, as in Type I Diabetes, in which T 
cells react against insulin-producing pancreatic islet cells to cause diabetes, or as 
in multiple sclerosis, described in detail below. Although the exact cause of most 
autoimmune diseases is unknown, several studies have detailed the presence of 
autoreactive CD4+ T cells in healthy individuals. It can then be assumed that in 
the context of autoimmune disease, these cells are either improperly regulated or 
improperly activated by cytokines in their environment and in turn express factors 
to promote inflammation. Understanding the factors that are required for CD4+ T 
cell pathogenicity in autoimmune disease, either in the signals required for their 
generation or the signals they produce to promote their pathogenic effector 
functions, could offer insight into identification of possible therapeutic targets.  
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Multiple Sclerosis 
 
 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS 
with genetic and environmental associations. Familial studies as well as 
geographic and ethnic population studies have demonstrated increased risk for 
disease among close family members of MS patients as well as in certain ethnic 
demographics [38].  MS is characterized by demyelinating lesions in the brain 
and spinal cord. Demyelination describes the loss of myelin, the layer of lipids 
and proteins that insulate neuronal axons. Demyelination of axons during MS 
leads to inefficient transmission of neuronal signals and reduced control of motor 
and cognitive functions. These inflammatory lesions vary widely in space, time, 
and cellular composition, and their location impacts the clinical manifestation of 
disease [42]. Symptoms are highly diverse in category and severity, within and 
across patients, and include spasticity, pain, vision loss, fatigue, and paralysis 
[43]. 
 
Current dogma states that MS is an autoimmune disease. The presence of 
inflammatory lesions in the CNS in the absence of infection, as well as the 
relative effectiveness of immunomodulating drugs, is suggestive of autoimmunity. 
Further, Genetic studies in MS patients have identified immune molecules, 
especially HLA-DR (encoding specific human MHC II loci) and IL-7 receptor 
alleles as being strongly associated with MS [39]. These factors also suggest the 
involvement of autoreactive CD4+ T cells. Current models of MS propose that 
myelin-specific T cells are primed in the periphery by unclear mechanisms and 
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gain access into to the CNS parenchyma. Once there, they activate resident and 
recruited inflammatory cells, including microglia, macrophages, monocytes, and 
granulocytes, to express mediators such as TNF-α, reactive oxygen species, and 
IFN-γ [40, 41].  The broad heterogeneity of lesions, symptoms, and clinical 
manifestations makes effective treatments elusive and suggests the involvement 
of diverse inflammatory mechanisms. 
 
Again, as in most autoimmune diseases, it is the activation rather than existence 
of self-reactive T cells that will induce MS. Several studies have determined that 
healthy individuals have myelin-reactive T cells and yet are spared disease [44]. 
Understanding the processes controlling autoreactive CD4+ T cell 
encephaliotogenicity, including T cell activation, homing to the CNS, and the 
factors produced to promote damage, will result in effective therapies that could 
be tailored to control any stage of MS. 
 
Experimental Autoimmune Encephalitomyelitis 
 
 
The most widely used model for CNS-targeted autoimmune demyelination is the 
rodent model of experimental autoimmune encephalomyelitis (EAE). Used as a 
model for human multiple sclerosis, EAE has been used to analyze the 
properties of pathogenic T cells [45]. EAE requires peripherally expanded myelin-
antigen-specific effector CD4+ T cells to infiltrate the CNS, typically resulting in 
an ascending paralysis in C57Bl/6 mice. Scoring rubrics are used to quantify 
disease severity over time. The disability that develops in these mice is 
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correlated with immune cell infiltration into the CNS parenchyma and a loss of 
myelin, similar to the pathology seen in MS.  Induction of EAE in different inbred 
strains of mice can induce various clinical courses which reflect different 
phenomenology of MS. The immunization of C57Bl/6 mice induces a chronic 
ascending paralysis, while SJL mice display relapsing-remitting forms of EAE. In 
other mouse strains, EAE presents with more ataxia and imbalance than 
paralysis, which is thought to result from leukocyte infiltration into specific regions 
of the CNS [46-51]. EAE, in any form, offers a model to investigate the priming of 
T cells, their homing to the CNS, and how those cells induce damage upon 
crossing the blood brain barrier. 
 
EAE can be induced in mice by either active immunization or adoptive (passive) 
transfer of myelin-reactive T cells. In active immunization, naïve mice are 
immunized with neuroantigen in the presence of adjuvant. In C57Bl/6 models, 
mice are immunized with a peptide fragment from myelin oligodendrocyte protein 
(MOG35-55) with complete Freunds adjuvant (CFA) and pertussis toxin to induce 
EAE typically within 12-14 days.  Active immunization models are used to 
determine disease properties within a single host, including the contribution of 
the innate response to adjuvant and factors that promote disease development 
and abrogation. In adoptive transfer models, CD4+ T cells are recovered from 
either immunized mice or naïve mice with a TCR specific for myelin antigen. 
CD4+ cells are polarized and expanded in culture with recombinant cytokines 
and antigen and transferred into naïve hosts.  This model is useful to determine 
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the requirements for any particular component of disease during the priming, 
polarization, or effector phase. Furthermore, transfer of encephalitogenic CD4+ 
Th cells into naïve mice eliminates the potentially confounding effects of the 
adjuvant on the host inflammatory and immune response.  In either case, EAE is 
a useful model to determine the critical properties of the CD4+ T cells which 
mediate disease. 
 
Th Effector Phenotypes in EAE 
 
Active immunization and adoptive transfer models of EAE have significantly 
contributed to our understanding of the relevance of CD4+ T cell lineages in 
autoimmune diseases like MS [52, 53].  If MS is mediated by autoreactive CD4+ 
T cells, it seems apparent that determining the critical CD4+ T cell lineage for MS 
initiation or progression could ultimately lead to better therapeutic targets. What 
is less apparent is whether EAE and MS are mediated by a single CD4+ T cell 
lineage and which molecules or properties are absolutely critical for individual 
subsets to promote encephalitogenicity. 
 
Historically, it was believed that EAE and MS were Th1-mediated.  A high 
frequency of IFNγ-producing T cells are found in the CNS and periphery of mice 
with actively-induced EAE, and patients with MS have high levels of IFN-γ in 
lesions located in CNS lesions and IFN-γ-producing myelin reactive T cells in the 
periphery [54-57]. Furthermore, in EAE, culturing myelin-specific CD4+ T cells in 
the presence of IL-12 prior to transfer, thereby promoting Th1 development and 
expansion, confers encephalitogenicity [58].  However, paradoxically, mice 
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deficient in IFN-γ, the IFN-γ receptor, or IL-12p35 are highly susceptible to EAE, 
though IL-12p40-deficient mice are completely resistant [58-61].  
 
Following the discovery of Th17 cells, the contribution of Th1 cells was 
reconsidered. IL-17A is expressed in the blood and cerebrospinal fluid of MS 
patients, as well as by CD4+ and CD8+ T cells in active MS lesions [62-64]. Mice 
deficient in IL-17A and/or IL-17F fail to develop severe EAE by active 
immunization, though they are not completely resistant [65, 66]. The contribution 
of Th1 cells to EAE was partially clarified when in 2000, Oppmann et al. 
demonstrated that IL-12p40 forms a heterodimer with IL-23p19 to form IL-23 [67]. 
This discovery led to two important observations: first, IL-23p19-deficient mice 
were completely resistant to EAE and second, IL-23 promotes Th17 terminal 
differentiation and pathogenicity [68-70].  Indeed, several groups have since 
demonstrated that the pathogenicity Th17 cells in EAE is critically tied to IL-23 
exposure rather than the intensity of IL-17 production.  Polarization with TGF-β 
and IL-6 alone can promote ROR-γt and IL-17 production, but encephalitogenicity 
is not conferred until Th17 cells are exposed to IL-23 [71-73]. Thus, in the 
absence of either of the IL-23 subunits--but not IL-12p35--Th17 cells could not 
expand in the CNS and mediate disease [68, 70]. 
 
These data suggested that IL-23-driven Th17 cells, and not IL-12-driven Th1 
cells, were the critical mediators of EAE.  However, it could not be denied that 
Th1 cells, or at least factors involved in Th1 differentiation and function, 
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contributed heavily to EAE development. Furthermore, if Th17 cells drive MS, 
what could explain the previously mentioned presence of Th1 cells in patients 
with MS. Mice deficient in T-bet, the master regulator of Th1 transcription, and 
STAT4, a regulator of IL-12 signaling on Th1 cells, were shown to be relatively 
resistant to EAE [74, 75].  Polarization of cells with IL-12 to promote Th1 
responses – and suppress IL-17 production—can promote EAE in adoptive 
transfer models [58]. Furthermore, mice deficient in hallmark Th17 molecules 
RORγt and IL-17 are not completely resistant to EAE [21, 65, 66].  
 
In 2008, Kroenke et al. demonstrated that myelin antigen-specific CD4+ T cells 
polarized with either IL-12 or IL-23 to promote IFN-γ or IL-17 production, 
respectively, could induce EAE via similar and distinct pathways [76]. Despite 
inducing EAE with similar incidence, severity, and time from onset to peak, the 
two models appeared to promote different cytokine and chemokine profiles and 
histological features. Mice that received IL-23-polarized cells had higher 
proportions of granulocytes in the CNS at peak disease, while IL-12-polarized 
recipients had a higher proportion of inflammatory monocytes and macrophages. 
Furthermore, IL-12 and IL-23-mediated EAE responded differently toTh1- or 
Th17-associated cytokine neutralizing antibody administration. These data 
demonstrated that Th1-mediated EAE and Th17-mediated EAE appeared to be 
distinct models of CNS-targeted autoimmune disease. These models have since 
been useful in determining the factors required for pathogenicity in one 
population versus the other and, ostensibly, better delineate the two effector 
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populations.  Further studies have suggested that some patients with MS may 
have a Th1 or Th17 bias, which could significantly alter response to treatment as 
well as suggest a mechanism of better-targeted therapies [77-80].  
 
These studies raised important questions about reported data from IL-23-
deficient systems: if IL-12 polarization can promote Th1 encephalitogenicity, why 
are IL-23-deficient mice completely resistant to EAE? IL-23R-deficient mice 
appear to have normal Th1 development and function in response to T. gondii 
infection, which is typically cleared by the Th1 response, so why are these 
functional Th1 cells unable to induce EAE [70]?  Unfortunately, adoptive transfer 
studies of Th1 and Th17 cells could not eliminate the possibility of IL-23 
expression in IL-12-mediated transfers during either the in vivo priming phase, 
the in vitro polarization, or by the host following transfer. Therefore it is unclear if 
unmeasured IL-23 exposure is critical for IL-12-polarized Th1-mediated EAE. 
Furthermore, as previously described, Th17 cells polarized in the presence of IL-
23 are pathogenic and plastic in autoimmune disease. The conversion from an 
IL-17-producer to an IFN-γ-producer is also promoted by IL-12 in vitro and 
requires T-bet. This raises the question of whether IL-12-polarized cells could 
simply be expanded exTh17s cells, and whether true Th1 cells play any role at all 
in EAE. Lastly, IL-23 is absolutely required for Th17 cell pathogenicity in EAE. Is 
it possible that the IL-23-driven epigenetic reprogramming that converts a Th17 
cell to an exTh17 cell is required for CD4+ T cell encephalitogenicity? 
 
Research Focus and Outline 
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Collectively, these data outline a possible model: IL-23 signaling on Th17 cells 
promotes T-bet expression, which, via transcriptional and epigenetic 
reprogramming and the support of continued IL-23 or IL-12 exposure, induces 
Th17 cells to become pathogenic exTh17 cells. This model would explain the 
requirement for both IL-23 and T-bet, two factors which were previously 
considered to belong to distinct lineages, and bring them together to promote a 
single powerful effector population. This model would also eliminate the 
contribution of bona fide Th1 and stable Th17 cells in EAE, and undermine the 
discoveries that IL-12- and IL-23-polarized cells induce EAE with distinct 
properties. Furthermore, it would suggest that in this particular model of 
autoimmunity, any IL-17 producing CD4 T cell is simply on a developmental 
pathway to become an IFN-γ producer, and Th1, Th17, and exTh17 cell 
differentiation and involvement would require reexamination in other models. This 
model can be explored by asking two questions:  can IL-12 promote EAE 
independently of IL-23, and is Th17 cell plasticity absolutely required for Th17 
cell encephalitogenicity.  These questions are addressed with the following aims: 
 
Aim 1, Chapter 2: Demonstrate that IL-12 polarized cells can induce EAE in the 
complete absence of IL-23. This novel finding will fortify the belief that bona fide 
IL-12-polarized IL-23-independent Th1 cells do have a place in CNS 
autoimmunity and that their contributions are distinct from Th17 cells.  
AIM 2, Chapter 3: Demonstrate that stable T-bet-deficient Th17 cells can induce 
EAE following adoptive transfer, and remain stable following the onset of 
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disease. These data will demonstrate that Th17 cells do not require the property 
of plasticity to be pathogenic. However, stable Th17 cells are less potent at 
inducing EAE.  
Aim 3, Chapter 4: Examine if the diminished potency of T-bet deficient Th17 
cells is related to a deficiency in homing to the CNS.  
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CHAPTER II 
IL-23 is dispensable in an IL-12-driven model of EAE 
 
Introduction  
 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the 
central nervous system (CNS). Inflammatory cells gain access to the CNS, drive 
multifocal lesion formation and cause damage to the myelin sheath that insulates 
axons. MS is a heterogeneous disease with considerable diversity in the clinical 
course, symptoms, and therapeutic responsiveness to disease-modifying 
therapies [1]. Despite the efforts of numerous research groups, validated 
biomarkers have yet to be identified that are predictive of relapse rate, disability 
progression or therapeutic response profiles [2-4].  
 
Experimental autoimmune encephalomyelitis (EAE) is an autoimmune 
demyelinating disease in laboratory animals that simulates many of the clinical 
and histopathological features of MS.  EAE can be induced via active 
immunization of susceptible inbred mouse strains with myelin antigens emulsified 
with Freund’s Complete Adjuvant (CFA).  Alternatively, it can be induced by the 
adoptive transfer of primed and polarized myelin-antigen specific CD4+ T cells 
into naïve syngeneic hosts. In most adoptive transfer models of EAE, it is
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necessary to stimulate primed CD4+ T cells in vitro with antigen in the presence 
of either recombinant IL-12 or IL-23 for several days prior to transfer, as 
exposure to either IL-12 or IL-23 is crucial for the acquisition of encephalitogenic 
properties by CD4+ T cells. However, the relative roles of IL-12 and IL-23 in EAE 
and MS, and the degree to which the molecules that are induced downstream of 
their signaling overlap or are independent, are matters of controversy.  A great 
deal of research is currently focused on elucidating the mechanisms by which 
encephalitogenic T cells traffic to the CNS, penetrate the blood-brain-barrier 
(BBB), become reactivated in the target organ, recruit other leukocytes to 
nascent lesions and inflict damage to myelin and axons. 
 
IL-12 and IL-23 are structurally similar cytokines that are produced by myeloid 
cells to drive CD4+ T cell polarization [5]. IL-12 and IL-23 are heterodimers that 
share a common subunit, the IL-12p40 (p40) chain. The unique chains of IL-12 
and IL-23 are the IL-12p35 (p35) subunit and the IL-23p19 (p19) subunit, 
respectively.  Expression of the p35 and p19 subunits is tightly controlled on the 
transcriptional level, while expression of p40 is more promiscuous.  Myeloid cells 
produce bioactive IL-12 and IL-23 in response to ligation of pattern recognition 
receptors (PRRs), such as Toll-like receptors (TLRs), or ligation of costimulatory 
molecules such as CD40 on their cell surface. Both IL-12 and IL-23 signal 
through receptors that are also heterodimers and share a common chain, IL-
12Rβ1 subunit, complexed with IL-12Rβ2 and IL-23R, respectively.  The IL-12 
and IL-23 receptors are expressed on conventional CD4+ and CD8+ T cells, as 
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well as on innate lymphocytes including NK cells and NK T cells. IL-12 induces 
expression of the transcription factor T-bet and the signature cytokine IFN-γ 
resulting in the differentiation of Th1 cells [6].  Conversely, IL-23 induces 
expression of the transcription factor ROR-γt and stabilizes the phenotype of 
Th17 cells.   
 
IFN-γ-producing CD4+ T cells are found at high frequency in the CNS of mice 
with EAE as well as in MS lesions.  Hence, it was initially concluded that that 
myelin-reactive Th1 cells are the primary effector cells in autoimmune 
demyelinating disease. However, it was subsequently discovered that C57BL/6 
mice deficient in critical Th1-associated factors like IFN-γ, IL-12p35, or the IL-
12Rβ2 subunit are susceptible to EAE following active immunization with MOG35-
55 in CFA [7-10].  Conversely, C57BL/6 mice deficient in the IL-23p19 subunit or 
the IL-23R receptor subunit were absolutely resistant to EAE induced using the 
same protocol. This led to the revised theory that IL-23 modulated Th17 cells 
initiate the disease process [11-13]. The paradox raised by these collective data 
appeared to be resolved by the realization that Th17 cells are plastic [14-16]. In a 
number of experimental systems, IL-17 producing CD4+ T cells become unstable 
and upregulate the Th1 transcription factor T-bet [17-19]. This leads to the 
expression of IFN-γ and downregulation of IL-17, resulting in conversion into  
exTh17 cells.  Using fate-mapping mice, it was recently shown that a high 
frequency of the IFN-γ producing cells infiltrating the CNS of C57BL/6 mice 
immunized with MOG35-55 in CFA did at one time express iL-17 and are, in fact, 
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exTh17 cells [14].  ExTh17 cells are as of yet virtually indistinguishable from 
canonical Th1 cells, which ostensibly do not require IL-23 for their development.  
Interestingly, exposure of IL-6 and TGF-β-polarized Th17 cell lines to IL-12 
during rechallenge has also been shown to catalyze their conversion to the 
exTh17 phenotype, on a population level, in vitro [20]. Currently, published 
adoptive transfer models of IL-12-driven EAE do not consider the contribution of 
unmeasured levels of IL-23 in the donor, culture, or host before or after culture. 
Therefore, it is questionable whether the required role of IL-23 is to promote 
plastic Th17 cell development, and whether transferred iL-12-polarized IFN-γ-
producing CD4+ T cells are actually IL-23-polarized exTh17 cells. 
 
We and others have described divergent characteristics of IL-12 and IL-23 
polarized myelin-reactive T cells in adoptive transfer models of EAE [12, 21].  
Several groups have used the IL-12/IL-23 adoptive transfer EAE model to 
determine the roles of individual cytokines, chemokines, and other factors in 
disease induced by each lineage, thereby establishing the degree to which the 
respective pathogenic pathways overlap. The discovery of exTh17 cells and the 
observation that IL-23, but not IL-12, is required in active immunization models of 
EAE, raise the question of whether “true” bona fide IL-12-polarized Th1 cells 
contribute to EAE pathogenicity in any context.   Understanding the contribution 
of Th1 cells versus extTh17 cells has translational relevance, as it is currently 
unclear if the clinical heterogeneity of MS patients reflects differences in the 
phenotype of dominant effector cell populations. 
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To further investigate these issues, we have developed IL-23- and IL-12-
independent adoptive transfer protocols. We hypothesized that the relative 
importance of stable Th17 cells, exTh17 cells and bona fide Th1 cells is context 
dependent.  Here, we polarize IL-12p40- and IL-23R-deficient MOG35-55-specific 
CD4+ T cells with IL-12 to generate highly polarized Th1 cells and transfer them 
into either IL-12p40-deficient or wild-type hosts. We demonstrate for the first time 
that IL-12-polarized Th1 cells can promote EAE in the complete absence of IL-23 
or its receptor. We characterize this novel IL-23-independent model of EAE in 
comparison to disease induced by stable Th17 cells.  We find that EAE induced 
by bona fide Th1 cells is actually more severe then that induced by highly 
polarized and stable Th17 cells.  We find that Th17 effector cells do not convert 
into ex-Th17 cells but remain stable following transfer into IL-12-deficient hosts.  
This suggests that expression of IL-23 in the donor, culture, and host is 
insufficient to drive Th17 cell plasticity. We also find that IL-23-independent Th1 
cells promote monocyte accumulation in the CNS by a partially CCL2-dependent 
pathway. Using multiplex cytokine analysis, we demonstrate that highly polarized 
IL-12 and IL-23-independent T cells invoke distinct inflammatory profiles. To 
assess translational relevance, we measure IL-23 and IL-12 expression in the 
serum of MS patients, rather than IFN-γ and IL-17, to define populations that 
produce relatively high levels of IL-12 or IL-23. We then compared the 
expression of IL-12 and IL-23-associated chemokines to assess global cytokine 
and chemokine expression patterns  
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Materials and Methods 
 
Mice: 8-16-week old IL-12p40-/-, IL-12Rβ2-/-  and IL-23R-/- mice werebred in 
specific pathogen-free conditions in the University of Michigan animal housing 
facilities. Wild-type C57BL/6 CD45.1 congenic mice were obtained from NCI 
Fredrick and held in specific pathogen-free conditions. All protocols were 
approved by the University of Michigan Committee on Use and Care of Animals. 
Immunization and T cell polarization: Mice were subcutaneously immunized with 
an emulsion of complete Freund’s adjuvant (CFA, Difco) and 100µg myelin 
oligodendrocyte glycoprotein peptide 35-55 MEVGWYRSP-FSRVVHLYRNGK 
(MOG35-55, Biosynthesis). 10-14 days later, draining lymph nodes were 
harvested and homogenized into a single cell suspension. Cells were cultured for 
96h in the presence of MOG35-55 and polarized under Th1-polarizing conditions 
with 6ng/mL rmIL-12 (R&D Systems) and anti-mouse IL-4 (clone A11B11) or 
Th17-polarizing conditions with 8ng/mL rmIL-23 (R&D Systems), 10ng/mL rmIL-
1α (PeproTech), 10ug/mL anti-mouse IL-4 and 10ug/mL anti-mouse IFNγ (clone 
XMG1.2). In some experiments, 5ug/mL anti-IL-23p19 (eBioscience) was added 
to Th1-polarizing conditions.  
Induction of EAE: After 96 hours of culture, the proportion of CD4+ cells was 
calculated using flow cytometry. 2x106 IL-12p40-/- CD4+ cells were injected into 
IL-12p40-/- mice.  IL-23R-/- and IL-12Rβ2-/- CD4+ cells were purified (>95%) using 
MACS and  3x106 were injected into wild type CD45.1 hosts. Mice were 
monitored daily for signs of disease as described previously.  
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Flow Cytometry: Intracellular staining was performed prior to adoptive transfer to 
assess CD4+ cell polarization. A subset of cells were stimulated with PMA 
(50ng/mL) and ionomycin (2µg/mL) in the presence of brefeldin A (10ug/mL) for 6 
hours. Following disease onset, myeloid and T cell populations and cytokine 
production were measured using surface and intracellular flow cytometry in the 
spleens and CNS. Spleens were homogenized and passed over a 70µm filter. 
Brains and spinal cords were homogenized using an 18g needle and syringe and 
digested in a solution of Collagenase A (1mg/mL, Roche) and DNase1 (1mg/mL, 
Sigma-Aldrich). Mononuclear cells were enriched using a 30/70 percoll gradient 
(GE Healthcare).  
Immunofluorescence:	  Mice were perfused 18 days after T cell transfer with 
Tyrode’s solution followed by 4% paraformaldehyde in phosphate buffered saline 
(PBS).  The spinal column was removed, postfixed for 24 hours in 
paraformaldehyde, and cryoprotected for 24 hours in 30% sucrose in PBS.  The 
spinal cord was isolated and frozen in OCT medium.  20 um sections were 
treated with 10 mM sodium citrate (pH 6.0, 70° C) for 15 minutes to increase 
antigen retrieval and incubated in blocking buffer (5% normal goat serum and 
0.1% Triton X-100 in PBS) for 1 hour.  Sections were incubated overnight in 
primary antibody diluted in blocking buffer, and after PBS washes, sections were 
incubated for 2 hours in secondary antibody diluted in blocking buffer.  Primary 
antibodies included syrian hamster anti-CD3e (1:70, BD), rat anti-MBP (1:300, 
Millipore), and mouse anti-SMI32 (1:2000, Covance).  Secondary antibodies 
included AlexaFluor 488-conjugated goat anti-rat IgG, AlexaFluor 594-conjugated 
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goat anti-mouse IgG, AlexaFluor 647-conjugated goat anti-syrian hamster IgG 
(1:300, Life Technologies).  Nuclei were labeled with DAPI (1:1000) for 5 
minutes.  Images were acquired on a Nikon A1 confocal microscope. 
Multiplex Protein Array: PBS-perfused brains and spinal cords were harvested at 
peak disease. Tissue was homogenized with an 18G needle in PBS and 
protease inhibitor. Homogenate supernatants were analyzed using a Milliplex 
Mouse 32-plex kit. Data was analyzed using Luminex Software.  
MS Patient Sample Collection and Analysis: Blood samples were taken monthly 
from MS patients not undergoing active treatment and divided into peripheral 
blood mononuclear cells for gene expression analysis and plasma for serum 
protein analysis. RNA was reverse-transcribed and analyzed for transcription 
factors (using somethign???) and normalized to four housekeeping genes. 
Serum protein levels were measured with a Milliplex Human Cytokine Kit and 
analyzed using Luminex software. Values are averages of 12 monthly visits. 
Statistical Analysis: Data were analyzed using Graphpad Prism software. P-
values were calculated using unpaired, two-tailed Mann-Whitney T-Tests.  
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Results 
 
Th1 cells can induce EAE independently of IL-23 
According to the current dogma, CD4+ T cells must be exposed to IL-23 become 
encephalitogenic. We have previously shown that myelin-specific CD4+ T cells 
stimulated with IL-12 and antigen express molecules typically associated with 
Th1 cells, including IFN-γ, IL-12R, and T-bet, but not Th17-associated factors. 
These cells induce EAE following transfer into naïve hosts. However, these 
adoptive transfer models of “Th1”-mediated EAE via the transfer of IL-12-
modulated CD4+ T cells have not considered the possibility that those donor 
cells are exposed to IL-23 during priming in vivo and convert to ex-Th17 cells 
during culture with IL-12.  
 
We questioned whether, under some circumstances, Th1 cells could induce EAE 
without the influence of IL-23 during the priming and effector phase. To 
investigate those questions and compare IL-23-independent Th1 cells with IL-12-
independent Th17 cells, we immunized mice deficient in IL-12p40 (which lack 
both IL-12 and IL-23) with MOG35-55 in CFA.  Draining lymph node cells were 
obtained 10-14 days later and cultured with antigen and recombinant IL-12 or IL-
23 to promote Th1 and Th17 cell differentiation, respectively. This experimental 
design allowed us to compare IL-12- and IL-23-modulated effector cells on an 
identical genetic background, primed in the same microenvironment with the 
same immunogenic stimuli.  Flow cytometric analysis following culture 
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demonstrated that myelin-reactive CD4+ T cells were highly polarized along their 
respective lineages. Specifically, IL-12p40-/- Th1-polarized CD4+ cells contained 
a high percentage of IFN-γ+IL-17- single producers and very few IFN-γ+IL-17+ 
double producers or IFN-γ-IL-17- single producers.  Conversely, IL-12p40-/- Th17-
polarized cells lines contained a high percentage of IFN-γ-IL-17+ single producers 
and very few IFN-γ+IL-17+ double producers or IFN-γ+IL-17- single producers 
(figure 2.1a). IL-23-polarized IL-12p40-/- Th17 cells also produced significantly 
higher levels of GM-CSF, consistent with previous reports that IL-23 
preferentially promotes GM-CSF production by CD4+ T cells [22, 23].  
 
We next transferred polarized IL-12p40-/- Th1 or Th17 cells into naïve CD45.1 
congenic IL-12p40-/- hosts.  We found that IL-12p40-/- Th1 cells induce EAE in IL-
12p40-/- hosts at an incidence that is actually higher than that induced by IL-
12p40-/- Th17 cells (100% versus 65%) (figure 2.1b). These results were 
reproduced when IL-12p35-/- Th17 cells were transferred into IL-12p35-/- hosts 
and IL-23p19-/- Th1 cells were transferred into IL-23p19-/- hosts (data not shown).  
At peak disease, we recovered spinal cord mononuclear cells for analysis of 
cytokine production via flow cytometry. CNS infiltrating Th1-polarized IL-12p40-/- 
donor cells maintained a high frequency of IFN-γ+IL-17- CD4+ cells, and low 
frequencies of IFN-γ+IL-17+ and IFN-γ-IL-17- producers (figure 2.1c). 
Surprisingly, Th17-polarized IL-12p40-/- donor CD4+ T cells maintained a high 
frequency of IFN-γ-IL-17+ producing T cells and low frequencies of IFN-γ+IL-17+ 
and IFN-γ+IL-17- producers, similar to their profile immediately prior to transfer.  
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These data suggest that IL-12p40-/- CD4+ T cell exposure to IL-23 in vitro is not 
sufficient for exTh17 development; rather, Th17 plasticity requires at least an 
early or continued exposure to IL-12 or IL-23 or both following immunization and 
adoptive transfer. Irrespective of the lineage of donor cells, IL-12p40-/- host CD4+ 
T cells produced little to no IL-17 or IFN-γ following disease onset (data not 
shown).  
 
Using a complimentary approach, IL-12Rβ2-/- and IL-23R-/- mice were primed with 
MOG35-55 in the presence of CFA. IL-23R-/- lymph node cells were cultured under 
Th1 conditions and IL-12Rβ2-/- lymph node cells were cultured under Th17 
conditions. These experiments eliminate the possibility that myelin-reactive 
effector T cells are inadvertently exposed in vitro to small quantities of IL-12 or 
IL-23 contaminants in media prior to adoptive transfer. Following polarization, IL-
23R-/- CD4+ T cells had a higher frequency of IFN-γ+IL-17- CD4+ T cells than IL-
12Rβ2-/- Th17 cells and a lower frequency of IFN-γ-IL-17+ cells (figure 2.1d). IL-
23R-/- CD4+ T cells had few IFN-γ-IL-17+ or IFN-γ+IL-17+ cells. Polarized cells 
were CD4+-purified (>92% purity) and transferred into wild-type CD45.1+ hosts.  
 
We found that IL-23R-/- Th1 cells and IL-12R-/- Th17 cells induced EAE with 
comparable incidence, kinetics and mean peak severity (figure 2.1e). Shortly 
following clinical onset, mononuclear cells were harvested from the CNS, stained 
intracellularly and analyzed by flow cytometry to assess cytokine expression.  
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Figure 2.1: Th1 and Th17 cells do not require IL-23 and IL-12, respectively, for the 
acquisition of encephalitogenic properties. (A-C) IL-12p40-/- (p40-/-) mice were immunized with 
MOG35-55 emulsified in CFA. Lymph nodes were harvested and cultured with antigen and Th1 
polarizing conditions or Th17 polarizing conditions. A) After four days of culture, a subset cells 
were stimulated with PMA and ionomycin in the presence of brefeldin A and analyzed for cytokine 
expression with flow cytometry. Frequencies indicate cytokine-positive cells within CD4+ gate. B) 
IL-12- or IL-23-polarized IL-12-40-/- T cells were injected into naïve IL-12p40-/- hosts. Hosts were 
monitored daily for signs of EAE. C) Following EAE onset, mononuclear cells were harvested 
from the spinal cords of sick mice and analyzed for intracellular cytokine expression. Data shown 
represents frequencies of cytokine-producing cells within the CD4+and CD45.1 (donor) gate. (D-
F) IL-23R-/- and IL-12Rβ2-/- mice were immunized as described and lymph node cells were 
cultured with antigen and Th1 or Th17 conditions, respectively. D) Flow cytometry was used to 
determine the frequencies of cytokine-positive cells. Frequencies indicate cytokine-positive cells 
within CD4+ gate. E) CD4+ cells were purified from IL-23R Th1 or IL-12Rβ2-/- Th17 cultures and 
injected into naïve wild-type CD45.1 congenic hosts (WT). F) Following disease onset, 
mononuclear cells were recovered from the spinal cords of sick mice. Cells were stimulated with 
PMA and ionomycin in the presence of brefeldin A and analyzed for CD4+ cytokine expression 
using flow cytometry.  Data shown represents frequencies of cytokine-producing cells within 
CD4+ CD45.2 (donor) gate.
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Donor CD4+ T cells were stable, as IL-23R-/- CD4+ cells maintained a higher 
frequency of IFN-γ+IL-17- cells and donor IL-12Rβ2-/- CD4+ cells maintained a 
higher frequency of   IFN-γ-IL-17+ cells. As seen in the IL-12p40-/- transfers, 
despite exposure of IL-12Rβ2-/- CD4+ T cells to IL-23 following immunization, 
culture, transfer, and disease progression, IL-12Rβ2-/- Th17 cells remained stable 
(figure 2.1f), suggesting that Th17 plasticity may be dependent on IL-12, and not 
IL-23, in these models. 
 
Highly polarized Th1 cells trigger the formation of monocyte-rich CNS infiltrates 
We next analyzed the cellular composition of CNS infiltrates in Th1 versus Th17 
recipients. Mice that received Th1-polarized IL-12p40-/- cells had higher 
frequencies and absolute numbers of CD45hiCD11b+Ly6c+Ly6g- monocytes in 
the brain and spinal cord infiltrates, and significantly lower frequencies and 
absolute numbers of CD45hiCD11b+Ly6c+Ly6g+ granulocytes in the brain when 
compared to IL-12p40-/- mice that received Th17-polarized IL-12p40-/- (figure 
2.2a). We also observed similar frequencies of monocytes and significantly lower 
frequencies of granulocytes in the spleens. Similarly, at peak disease, recipients 
of IL-23R-/- Th1 cells had significantly higher numbers and proportions of 
monocytes in the brain relative to recipients of IL-12Rβ2-/- Th17 cells. However, 
there were no significant differences between monocyte and granulocyte 
frequencies in spinal cord or spleen (figure 2.2b). Differences in observed  
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Figure 2.2. IL-23-independent Th1 cells promote enhanced monocyte recruitment to the 
CNS. (A) MOG35-55-specific IL-12p40-/- (p40-/-) Th1 or Th17 cells were adoptively transferred into 
p40-/- hosts as previously described. (B) MOG35-55-specific IL-23R-/- Th1 or IL-12Rβ2-/- Th17 cells 
were adoptively transferred into CD45.1 wild-type hosts. After disease onset, mononuclear cells 
were harvested from the CNS and spleen. Myeloid populations were analyzed using flow 
cytometry. Frequencies are based on CD11b+ CD45hi cells. (C) MOG35-55-specific IL-23R-/- Th1 
cells were transferred into wild-type or CCR2-/- mice and monitored daily for signs of EAE. 
(*p<.05) 
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granulocyte and monocyte frequencies in the IL-12p40 transfer models 
compared to the cytokine receptor knockout transfer models be explained with 
compensatory effects of wild-type host cells on myeloid cell recruitment in the 
latter models. Furthermore, there may be requirements for IL-12p40 signaling on 
other cell populations that would be lost in IL-12p40-/- mice, possibly altering the 
cellular composition during disease. The observation that the cellular composition 
of CNS infiltrates differ between EAE induced by highly polarized and stable Th1 
versus Th17 effectors is consistent with our previously published observations 
which describe similar phenomena using wild-type donors and hosts [21]. To 
determine whether monocyte recruitment is critical for the pure Th1-driven 
disease, we transferred IL-23R-/- Th1 cells into mice deficient in CCR2. CCR2 is 
enriched on monocytes relative to neutrophils and it binds to CCL2, which is 
expressed at sites of inflammation. CCR2 function is required for normal 
monocyte recruitment to the CNS during EAE [24, 25]. In the absence of CCR2 
in host mice, IL-23R-/- Th1 cells induce a significantly milder and delayed disease 
relative to wild type hosts (figure 2.2c). 
 
 
Chemokine and cytokine profiles in the CNS reflect the cellular composition of 
CNS infiltrates 
Differences in cellular composition in the CNS of IL-12p40-/- hosts likely reflect 
differences in cytokine and chemokine profiles in mice with highly polarized 
models of Th1- or Th17-mediated EAE.  At peak disease, supernatants from  
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Figure 2.3. Highly polarized Th1 and Th17 cells induce different protein profiles and 
infiltration patterns in the CNS. IL-12p40-/- Th1 and Th17 cells were adoptively transferred into 
IL-12p40-/- mice as described previously. Following disease onset, brains and spinal cords were 
homogenized in the presence of protease inhibitors. Supernatants were isolated and analyzed 
using Luminex multiplex protein assay to measure (A) cytokines and (B) chemokines from a 
mouse inflammation panel. (C) IL-23R-/- Th1 cells or IL-12Rβ2-/- Th17 cells were adoptively 
transferred into wild-type mice to induce EAE. Following disease onset, frozen sections were 
prepared for immunofluorescence and labeled with anti-CD3 and SMI-32. (*p<.05). 
C 
CD3	  SMI-­‐32	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Figure 2.4. Inflammatory Response in the CNS induced by highly polarized Th1 or Th17 
cells.  IL-12p40-/- Th1 and Th17 cells were adoptively transferred into IL-12p40-/- mice as 
described previously. Following disease onset, brains and spinal cords were homogenized in the 
presence of protease inhibitors. Supernatants were isolated and analyzed using Luminex 
multiplex protein assay.  Non-metric multidimensional scaling was performed (top) and principle 
component analysis (PCA) was used to determine the individual parameter contribution to formed 
groups (middle and bottom). 
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CNS tissue homogenates were isolated from IL-12p40-/- recipients of either Th1 
or Th17 IL-12p40-/- cells. Using a multiplex protein array, protein levels of several 
cytokines and chemokines were analyzed. As expected, we found higher levels 
of IL-17 and lower levels of IFN-γ in the both the brain and spinal cord of Th17 
recipients relative to Th1 recipients (figure 2.3a). In fact, we typically found 
extremely low levels of IFN-γ in both the brain and spinal cord in the Th17 
recipients, and most samples had an IFN-γ concentration below the limit of 
detection. In spinal cords, but not brains, of Th1 recipient mice, we found higher 
levels of TNF-α, IL-6, and surprisingly, GM-CSF (figure 2.3a). Higher levels of 
these proinflammatory cytokines may underlie the increased disease severity or 
incidence in the Th1 IL-12p40-/- transfers. We also observed higher levels of 
CXCL9 and CXCL10, which are chemokines known to be expressed in the CNS 
in response to IFN-γ (figure 2.3b) [26-28].  CCL2 levels were also relatively high 
in the Th1 recipients, consistent with our observation that “pure “ Th1 cells induce 
monocyte-rich infiltrates (figure 2.3b). Surprisingly, CXCL1, which binds to 
CXCR2 expressed by neutrophils, was also elevated in Th1 recipients (figure 
2.3b). Overall, these multiplex data suggest that IL-12p40-/- Th1 cells promote an 
enhanced inflammatory cytokine and chemokine profile in the CNS of IL-12p40-/- 
hosts relative to analogous Th17 transfers, likely owing to their potency to induce 
disease. Therefore, despite the complete absence of functional IL-23 in these 
adoptive transfer models of EAE, IL-12-polarized Th1 cells were potent inducers 
of inflammation. Furthermore, IL-23 polarization in vitro in the absence of IL-12 
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was insufficient to mount a similar response in IL-12p40-/- Th17-modulated 
disease. 
 
In order to assess the histological infiltration patterns in our highly polarized Th1 
and Th17-mediated transfers, lumbar spinal cord sections from wild-type mice 
that had received IL-23R-/- Th1 cells or IL-12Rβ2-/- Th17 cells were analyzed with 
immunofluorescence. In both groups, CD3+ cells associated with SMI-32, a 
marker of neuronal damage. Infiltration patterns in the parenchyma of mice that 
received IL-23R-/- Th1 were characterized as being localized on the periphery of 
the spinal cord, while IL-12Rβ2-/- Th17 recipients were marked with characteristic 
finger-like projections (figure 2.3c). Again, this is consistent with our previous 
wild-type adoptive transfer models of IL-12- and IL-23-mediated disease [21].  
 
While two-dimensional analysis of the serum levels of cytokines and chemokines 
was informative to determine relative expression on a per-protein basis, the 
advantage of a high-throughput multivariate assay such as a Luminex assay is to 
assess global protein expression patterns within the host and attempt to 
differentiate between pathologic groups. To accomplish such an assessment, we 
applied non-metric multidimensional scaling (NMDS) to the multiplex protein 
array data acquired from analysis of IL-12p40-/- Th1 and Th17 brain and spinal 
cord homogenates (figure 2.4, top). NMDS is an ordination technique that groups 
observations in space based on multivariate similarity. The more similar two mice 
were in global cytokine/chemokine production, the closer they would group in the 
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NMDS plot. We expected that recipient mice receiving Th1 and Th17 polarized T 
cells would form distinct groups if pathogenesis was different in these transfer 
models. Indeed, recipient mice formed distinct groups based on Th1 and Th17 
polarizations. Furthermore, brains and spinal cords within Th1 or Th17 groups 
were also distinct. Next, we used principle component analysis (PCA) as a 
second ordination technique to visualize the relative contributions of individual 
cytokines to the differences between Th1 and Th17 groups within each the brain 
(figure 2.4, middle) and spinal cord (figure 2.4, bottom). In agreement with the 
individual cytokine plots referenced in figure 2.3, the PCA demonstrated an 
inverse relationship between IL-17A and IFN-γ ,as they are nearly opposing 
vectors in the PCA biplots and were associated with Th1 and Th17 recipients, 
respectively. CXCL10 (IP-10), CXCL9 (MIG) and CCL2 (MCP-1) also associated 
with the Th1 group, while CXCL1 (KC) and G-CSF were associated with the 
Th17 group. In contrast, factors like GM-CSF and IL-1 are thought to promote 
Th17 responses, though they were found to be more important in the Th1 group 
in the spinal cord. This may help explain the increased potency of IL-12-polarized 
relative to IL-23-polarized IL-12p40-/- cells, though the mechanisms have yet to 
be determined. Overall, these data indicate that adoptive transfer of Th1 or Th17 
IL-12p40-/- cells induces distinct expression of cytokines and chemokines, 
resulting in two novel mutually exclusive disease groups in EAE 
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Table 2.1. Correlation of IL-12 and IL-23 serum concentration with proinflammatory cytokines and 
chemokines within IL-12-skewed and IL-23-skewed MS patients, respectively. 
Group Cytokine p-value r R squared 
IL-17A (serum) 0.15 0.74 0.55 
IFN-γ (serum) 0.17 0.72 0.51 
IL-17A (MBP) 0.02 -0.93 0.87 
IFN-γ (MBP) 0.06 -0.85 0.73 
GM-CSF 0.01 0.91 0.95 
TNF-α 0.93 -0.06 0.003 
CXCL10 0.17 -0.72 0.52 
CCL2 0.56 -0.36 0.13 
CXCL5 0.97 0.02 0.0007 
IL-12-Skewed 
(IL-12 
correlation) 
CXCL1 0.54 0.37 0.14 
IL-17A (serum) 0.014 0.51 0.26 
IFN-γ (serum) 0.74 -0.07 0.005 
IL-17A (MBP) 0.91 -0.03 0.0007 
IFN-γ (MBP) 0.95 0.01 0.0002 
GM-CSF 0.07 0.38 0.14 
TNF-α 0.92 -0.02 0.0005 
CXCL10 0.33 -0.21 0.05 
CCL2 0.97 -0.008 5.832e-005 
CXCL5 0.91 
 
-0.02 
 
0.0005 
 
IL-23-Skewed 
(IL-23 
correlation) 
CXCL1 0.9248 0.02085 0.0004346 
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Figure 2.5. Inflammatory Response in the periphery of MS patients suggests IL-12 and IL-
23 skewed groups.  Blood samples from untreated MS patients was drawn monthly and 
processed for (A) RNA, (B) ELIspot and (C) multiplex protein array analysis. IL-12-skewed and IL-
23-skewed patients were compared for (A) relative expression of T-bet and Ror-γt, (B) MBP-
specific IL-17 and IFN-γ, and (C) serum protein concentration. D) Data from protein arrays in IL-
12- and IL-23-skewed and unskewed groups were analyzed using NMDS. (* p<.05) 
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Analysis of Serum Protein Levels from MS Patients Suggests Grouping Based on 
IL-12 or IL-23 Expression 
Thus far, we have demonstrated that IL-23-independent Th1 cells and IL-23-
independent Th17 cells mediate distinct forms of EAE. Translating these data to 
MS research is challenging, as MS is highly heterogeneous and complex relative 
to inbred mouse models of EAE. Several groups have analyzed datasets from 
human studies in an attempt to categorize groups of patients who exhibit patterns 
of cytokines, clinical course, and response to therapy with the goal of identifying 
biomarkers and more specific therapeutic targets [29]. A number of studies have 
grouped MS patients based on relative IFN-γ and IL-17 production as a proxy of 
Th1- or Th17-mediated disease. However, these classifications do not take into 
account the contribution of exTh17 cells, and as of yet there are no markers in 
humans or mice to distinguish between exTh17 cells from Th1 cells. Therefore, 
we collected data from MS patients not undergoing active treatment to determine 
whether IL-12 and IL-23 expression would correlate with cytokine and chemokine 
profiles seen in highly polarized Th1 and Th17 adoptive transfer models of EAE. 
Serum and PBMCs were collected monthly and analyzed using a multiplex 
protein array and qPCR. Using data from the protein array, groups were defined 
as being “IL-23-skewed” if the twelve-month average serum concentration of IL-
23 was at least two-fold higher than IL-12, “IL-12-skewed” if the serum 
concentration of IL-12 was at least two-fold higher than IL-23. Those that fell 
outside either definition were considered “unskewed”. Within these definitions, 
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71% of patients were IL-23-skewed and 14% were IL-12-skewed, and 14% of 
patients were unskewed. To determine whether the expression level of 
classically Th1- or Th17-associated cytokines or chemokines correlated with IL-
12 or IL-23 expression in those respective skewed groups, we used regression to 
determine r values, R squared values, and p-values (Table 2.1). Within the IL-12-
skewed group, only IL-17A produced in response to myelin basic protein 
correlated negatively (p=0.02, r= -0.93) with IL-12 serum concentration. Within 
the IL-23-skewed group, serum concentrations of IL-17A were positively 
correlated (p=0.014), though these data poorly fit the model (R2=.26). 
 
We also analyzed Th1 and Th17-associated chemokines and cytokines to 
directly compare their expression levels between IL-12-skewed and IL-23-
skewed patients. Patients in the IL-12-skewed groups had a higher ratio of tbx21 
to rorc gene expression than those in the IL-23-skewed group (figure 2.5a). We 
found no difference between IL-12- and IL-23-skewed patients in IL-17, IFN-γ, 
GM-CSF, TNF, CCL4, CCL2, or CXCL10 expression based on serum protein 
levels. Expression of GRO and neutrophil elastase (ELA) was significantly higher 
in IL-23-skewed patients (figure 2.5b).  
 
Although two-dimensional cytokine data from skewed human populations did not 
recapitulate the highly polarized data from our adoptive transfer experiments, we 
wanted to determine whether NMDS analysis would demonstrate global 
differences in cytokine and chemokine among MS patients grouped by IL-12 and 
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IL-23 expression, similar to the data seen in mice. Based on this analysis, IL-12-
skewed patients (A) formed a distinct group from IL-23-skewed patients (B), 
whereas unskewed patients were intermediate (figure 2.5d). This result is 
consistent with data from mouse experiments to support the hypothesis that IL-
12 and IL-23 expression levels could define global cytokine profiles and 
differentiate between MS patient populations. 
	  51	  
 
Discussion 
We questioned whether IL-12 and IL-23 could induce autoimmune disease via 
truly independent pathways. While we and others have proposed distinct 
mechanisms driving IL-12-mediated and IL-23-mediated EAE, these mechanisms 
did not consider the concept that IL-23 exposure leads to Th17 cell 
encephalitogenicity and plasticity. The discovery of Th17 cell plasticity suggested 
the possibility that IL-23 and IL-12 may have cooperative roles to promote 
disease via a singular pathway. Here, we demonstrated that IL-23 and IL-12 
polarization could promote CD4+ T cell encephalitogenicity independently of one 
another. To our knowledge, this is the first report of EAE development in the 
complete absence of IL-23. Surprisingly, we determined that IL-23-independent 
Th1 cells were more encephalitogenic than IL-12-independent Th17 cells, 
demonstrating that exposure to IL-23 is not sufficient for Th17 cell 
encephalitogenicity. Ongoing studies will examine the role of IL-12 in Th17 cell 
polarization and potency in EAE. 
 
We next compared the properties of these two highly polarized and mutually 
exclusive models of EAE. We described the distinct cellular and cytokine profiles 
of IL-12- and IL-23-independent adoptive transfer models of EAE. Following 
transfer, IL-12-independent Th17 cells were stable and did not exhibit Th17 cell 
plasticity, which could be associated with the reduced potency of IL-12-
independent Th17 cells. Furthermore, it suggests that IL-12, rather than IL-23, 
may play a significant role in Th17 cell plasticity in vivo. Relative to IL-12-
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independent Th17-mediated adoptive transfer models of EAE, IL-23-independent 
Th1 models promote a typical but highly polarized Th1-associated cytokine 
response, as well as enrichment in monocyte accumulation and concurrent 
increases in monocyte homing chemokine expression in the CNS. We also 
concluded that IL-23-independent Th1 transfer models of EAE are partially 
dependent on the monocyte homing chemokine CCL2. We observed higher 
levels of proinflammatory cytokines in the CNS of recipients of IL-12p40-/- Th1 
cells compared to Th17 cells, which could also be associated with the enhanced 
potency seen in the IL-23-independent Th1 cells. Differences between cytokine 
and chemokine levels are even more striking when analyzed holistically to 
determine global patterns.    
 
These highly polarized mouse models described the divergent and mutually 
exclusive roles of Th1- and Th17-associated factors without considering IFN-γ 
and IL-17A expression a priori. We applied this mechanism translationally to 
determine whether relative IL-12 and IL-23 serum levels would be indicative of 
distinct proinflammatory mechanisms. We grouped patients based on IL-12 and 
IL-23 expression and compared cytokine profiles between those groups. We 
found that on a per-cytokine basis, there were not differences between IL-12 and 
IL-23-skewed patient populations.  However global cytokine and chemokine 
expression analysis across an entire dataset determined that groups based on 
relatively higher IL-12- or IL-23 expression were indeed distinct from each other, 
and groups with similar levels of IL-12 and IL-23 were intermediate.  
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While these data were less striking relative to the observations seen in mice, we 
feel that analyzing the relative levels of IL-12 and IL-23 to determine whether 
distinct patient populations exist is a sensible method. Data from mouse models 
published here and elsewhere have suggested that in the consideration of the 
dispensability of IFN-γ and IL-17 during EAE and the phenomenon of Th17 cell 
plasticity, developing translational data which defines patients by IFN-γ and IL-17 
levels may not be informative. 
 
Differences between features of highly polarized Th1 and Th17-mediated EAE 
are informative in determining the mechanism of action and particular factors 
promoted by either cell type. Future studies attempting to understand monocyte 
recruitment, for example, could be facilitated by comparing the monocyte-rich 
highly polarized Th1 adoptive transfer models of EAE to analogous Th17 models. 
Furthermore, using IL-12- or IL-23-independent adoptive transfer models, 
intrinsic properties of these highly polarized CD4+ T cell subsets can be 
measured. Future experiments involve determining Th1- or Th17-specific 
homing, survival, and activation properties.  
 
The heterogeneity of multiple sclerosis and the individuals affected by it has 
made MS research challenging. Understanding cellular and molecular 
differences across patient groups could allow researchers to target therapies in 
patients with particular profiles. Here, we defined patient groups in ways that 
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reflect our mouse models to determine whether differences emerge similar to 
those seen in the mice.  Though the data based on patient groups based on IL-
12 and IL-23 expression were only striking when considering the entire cytokine 
and chemokine dataset, our data represents the global differences between 
patient populations. Datasets with more patients and measured parameters will 
refine the reported data here. However, we feel that defining groups of MS 
patients based on IL-12 and IL-23 levels is a reasonable method for defining 
different populations. 
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Summary 
In the MOG35-55 induced EAE model, autoreactive Th17 cells that accumulate in 
the central nervous system (CNS) acquire Th1 characteristics via a T-bet 
dependent mechanism. It remains to be determined whether Th17 plasticity and 
encephalitogenicity are causally related to each other. Here we show that IL-23 
polarized Tbet-/- Th17 cells are unimpaired in either activation or proliferation, and 
induce higher quantities of the chemokines RANTES and CXCL2 than wildtype 
(WT) Th17 cells. Unlike their WT counterparts, Tbet-/- Th17 cells retain an IL-
17hiIFN-γneg-lo cytokine profile following adoptive transfer into syngeneic hosts. 
This population of highly polarized Th17 effectors is capable of mediating EAE, 
albeit with a milder clinical course. It has previously been reported that the 
signature Th1 and Th17 effector cytokines, IFN-γ and IL-17, are dispensable for 
the development of autoimmune demyelinating disease.  The current study 
demonstrates that the “master regulator” transcription factor, T-bet, is also not 
universally required for encephalitogenicity.  Our results contribute to a growing 
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body of data showing heterogeneity of myelin-reactive T cells and the 
independent mechanisms they employ to inflict damage to CNS tissues, 
complicating the search for therapeutic targets relevant across the spectrum of 
individuals with multiple sclerosis. 
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Introduction 
 
Experimental autoimmune encephalomyelitis (EAE) is a CD4+ T-cell-mediated 
autoimmune disease of the central nervous system (CNS), widely used as an 
animal model of multiple sclerosis (MS).  Despite substantial progress in 
elucidating pathogenic pathways that drive EAE, the mechanisms employed by 
autoreactive T cells to initiate inflammatory demyelination and, hence, the 
effector functions that are critical for their encephalitogenicity, are largely 
unknown.  We and others have previously shown that IL-12-polarized Th1 and 
IL-23-polarized Th17 cells specific for the same myelin antigen are independently 
capable of inducing EAE following adoptive transfer into naïve syngeneic hosts 
[1, 2].  Surprisingly, full blown disease occurs in the absence of the signature Th1 
and Th17 cytokines, IFN-γ and IL-17A/F, either alone or in combination [3-5].  
More recently, the master regulatory transcription factor, T-bet, was identified as 
a critical molecule in the programming of encephalitogenic Th17 as well as Th1 
cells [6].  T-bet was originally described as a driver of Th1 differentiation via 
direct activation of the IFN-γ gene and upregulation of the IL-12 receptor β2 chain 
[7, 8].  Gocke et al. [9] subsequently reported that T-bet could also promote the 
differentiation of autoimmune effector Th17 cells by inducing IL-23 receptor 
expression.  
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Several laboratories have established a role for T-bet in the plasticity of Th17 
cells, particularly in their acquisition of Th1-like characteristics to become so 
called “ex-Th17” cells [10-12]. Fate mapping experiments using IL-17 reporter 
mice demonstrated that the majority of CD4+ T cells infiltrating the CNS of 
C57BL/6 mice actively immunized with a peptide of myelin oligodendrocyte 
glycoprotein (MOG35-55) are ex-Th17 cells [13, 14]. This observation has led 
some investigators to speculate that the plasticity of myelin-reactive Th17 cells is 
causally related to their acquisition of encephalitogenic properties. If they are 
correct then T-bet would be critical for the development of EAE based on its role 
in facilitating the transition of myelin reactive Th17 cells into ex-Th17 cells. In the 
current study we directly assess the requirement of T-bet expression in IL-23 
polarized, myelin-reactive T cells for the adoptive transfer of EAE.  We find that, 
unlike their WT counterparts, autoreactive T-bet-/- cells resist conversion to an ex-
Th17 phenotype upon in vitro or in vivo reactivation.  Moreover, these stable 
Th17 cells trigger the accumulation of myeloid cells in the spleen and CNS, 
thereby retaining the ability to induce EAE in WT as well as RAG2-deficient 
hosts. 
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Materials and Methods 
 
Mice: 8-12-week-old C57BL/6 wild-type, CD45.1 congenic, T-bet-/- and RAG2-/- 
mice were obtained from the Jackson Laboratory and housed in microisolator 
cages under specific pathogen-free conditions.  T-bet-/- and RAG2-/- mice were 
subsequently bred in our facility. All animal protocols were approved by the 
University Committee on Use and Care of Animals. 
Induction of EAE: Mice were injected subcutaneously with 100 µg MOG35-55 
MEVGWYRSP-FSRVVHLYRNGK (Biosynthesis) in complete Freund’s adjuvant 
(Difco). For induction of EAE by active immunization, inactivated Bordetella 
pertussis toxin was administered intraperitoneally on days 0 and 2.  
For induction of EAE by adoptive transfer, draining lymph nodes were harvested 
10-14 days post-immunization, homogenized, and passed through a 70-µm cell 
strainer (BD Falcon).  LNCs were cultured in vitro with MOG35-55 (50 µg/ml) under 
conditions favorable to the generation of Th17 cells (rmIL-23, 8 ng/mL; rm IL-1α, 
10 ng/ml; anti-IFN-γ (clone XMG1.2), 10 µg/mL; anti-IL-4 (clone 11B11), 10 
µg/mL).  2 x 106 CD4+ T cells were injected intraperitoneally, and mice were 
observed daily for signs of EAE as described previously [15].   
Flow cytometry: Spinal cords were harvested at peak disease, homogenized in 
DNase (1 mg/mL) and collagenase A (2 mg/mL) and incubated for 30 min at 37 
°C.  Mononuclear cells were isolated over a 30/70% Percoll gradient (GE 
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Healthcare).  Splenocytes were passed through a 70-µm cell strainer, ACK lysed 
and washed twice prior to analysis. For intracellular staining, cells were 
stimulated with PMA (50 ng/mL) and ionomycin (2µg/mL) in the presence of 
brefeldin A (10 µg/mL) for 6 h or with MOG35-55 for 24 h. Cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.5% saponin prior to incubation with 
flourochrome-conjugated antibodies. Flow cytometry was performed using a BD 
FacsCanto II. 
ELISA: Splenocytes were cultured with or without MOG35-55 (50 mg/ml) in a 96 
well plate (2 x 106 cells/ well).  Supernatants were collected at serial time points 
and analyzed by sandwich ELISA according to the manufacturer’s protocol 
(eBioscience).  In some experiments, cell culture supernatants were analyzed 
using luminex protein array according to the manufacturer’s instructions 
(Millipore). 
ELISPOT assay: The frequency of antigen-specific cytokine producers was 
determined following culture for 24 h in 96-well filtration plates (Millipore), with or 
without 50 µg/ml MOG35-55.  Antibodies from eBioscience were: anti-IL-17 (TC11-
18H10), biotinylated anti-IL-17 (TC11-8H4), IFN-γ (AN18) and biotinylated anti-
IFN-γ (R4-6A2).  Streptavidin–alkaline phosphatase (Southern Biotech) and an 
alkaline phosphatase substrate kit (Vector Laboratories) were used to identify 
trapped cytokine. Spots were counted using the CTL ImmunoSpot Analyzer 
(Cellular Technology) with ImmunoSpot software, and the number of spots in the 
medium-only wells subtracted to generate the data shown. 
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Statistical analysis: Statistical analyses were performed using GraphPad Prism 
statistical analysis software.  Group differences were analyzed by unpaired, two-
tailed Students t test.  P-values of 0.05 or less were considered significant. 
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RESULTS  
 
MOG35-55 immunized T-bet-/- mice generate a Th17 biased response and 
succumb to EAE 
The master transcription factor, T-bet, has been implicated in the pathogenesis of 
EAE and MS [16-19]. We revisited the role of T-bet in EAE by comparing the 
clinical courses of C57BL/6 T-bet-/- and WT mice following subcutaneous 
immunization with an emulsion of MOG35-55 in CFA and intraperitoneal injection 
of inactivated Bordetella pertussis toxin.  Ninety percent of T-bet-/- mice 
succumbed to moderate to severe EAE, although disease onset was slightly 
delayed compared with that of their WT counterparts (Fig. 1A).  Examination of 
cytokine expression by CNS mononuclear cells pooled from representative mice 
in each group, and by splenocytes harvested from individual mice at peak EAE, 
revealed skewing towards an IL-17+IFN-γ- profile in the T-bet-/- cohort (Fig. 1B 
and C). Splenocytes from immunized T-bet-/- mice produced significantly higher 
levels of IL-17 and lower levels of IFN-γ than splenocytes from WT mice in 
response to in vitro challenge with MOG35-55 (Fig. 1D).  
 
IL-23 polarized T-bet-/- Th17 cells are phenotypically stable in vitro and in vivo 
Collectively, these data suggested that in the absence of T-bet, inflammatory 
demyelination was mediated by myelin-reactive Th17 cells that resist conversion  
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Figure 3.1. MOG35-55 primed T-bet-/- mice mount an enhanced Th17 response and succumb 
to EAE. EAE was induced in WT and T-bet-/- C57BL/6 mice via immunization with MOG35-55 in 
CFA and administration of inactivated pertussis toxin. (A) WT (closed squares) and T-bet-/- (open 
squares) mice were rated on a daily basis for degree of neurological disability by an examiner 
blinded to genotype. Clinical scores for each cohort were averaged over two experiments with a 
total of 8-10 mice/group. (B) Mononuclear cells and (C) splenocytes from the CNS were 
harvested at peak EAE.  CNS mononuclear cells, pooled together from mice in each group, or 
splenocytes harvested from individual mice, were analyzed by intracellular staining and flow 
cytometry following stimulation with PMA and ionomycin for 6 h.  Representative flow cytometry 
plots are gated on CD4+ T cells. Each symbol represents an individual mouse and data shown 
are representative of three independent experiments. Bar represents mean. (D) Splenocytes 
obtained from MOG35-55-immunized WT (closed bars) and T-bet-/- (open bars) mice were cultured 
with either MOG35-55 at the indicated concentrations, PMA and anti-CD3, or medium only.  
Supernatants were collected at 96 hours and subjected to sandwich ELISA to measure cytokine 
levels. The data are shown as mean/+SEM of 5 mice per groups and are from one experiment 
representative of four experiments.  *** P<0.001;** P<0.01; * P<0.05 compared to WT control, 
unpaired, two-tailed Student’s t test. 
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to ex-Th17 cells.  In support of this hypothesis, MOG-primed T-bet-/- CD4+ T cells 
predominantly exhibited an IL-17+IFN-γ- profile following a 96 h culture with 
antigen plus recombinant IL-23 and IL-1β,  while a significant percent of WT 
CD4+ T cells cultured under the same conditions were IL-17-IFN-γ+ (Fig. 2A).  IL-
23 polarized T-bet-/- CD4+ T cells maintained a Th17 phenotype upon secondary 
challenge with MOG35-55 alone (Fig 2B and C).    Multiplex bead immunoassays 
revealed increased levels of RANTES and CXCL2 in supernatants from primary 
cultures of T-bet-/- Th17 cells by comparison with WT Th17 cells (Fig 2D). 
Conversely, the concentration of the IFN-γ-induced chemokine CXCL9 was 
relatively low in supernatants from T-bet-/- Th17 cell cultures. T-bet-/- cells also 
expressed GM-CSF at a lower frequency than WT cells during primary culture 
(Fig. 2A).  However, T-bet-/- and WT Th17 cells secreted comparable quantities 
of GM-CSF upon secondary challenge (Supporting Information Information Fig. 
1).  T-bet-/- and WT Th17 cells produced similar quantities of other cytokines and 
chemokines implicated in EAE pathogenesis, including IL-1α, IL-6, and G-CSF 
(Fig 2D). The majority of T-bet-/- Th17 cells upregulated activation markers and 
proliferated in response to antigen to a similar extent as their WT counterparts 
(Fig. 2E), indicating that their failure to acquire Th1 characteristics was not a 
consequence of insufficient antigen presentation or TCR engagement. The fact 
that a relatively high percentage of T-bet-/- cells expressed a 
CD44+CD69+CD25+CD62Lneg profile could reflect a less differentiated state [20].   
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Figure 3.2. IL-23 polarized T-bet−/− Th17 cells are stable in vitro (legend on next page). 
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Figure 3.2. IL-23 polarized T-bet−/− Th17 cells are stable in vitro. WT and T-bet−/− mice were 
immunized with MOG35–55/CFA. Ten to 14 days later, single cell suspensions of draining LN cells 
were cultured with MOG35–55 in the presence of IL-23, IL-1α, anti-IFN-γ, and anti-IL-4. (A) At 96 h 
cells were harvested, washed, and stimulated with PMA and ionomycin for 6 h prior to for 
intracellular staining and flow cytometry. The percentages of WT (black bars) and T-bet−/− (white 
bars) CD4+ T cells that expressed cytokines as indicated were averaged over seven experiments 
with 4–6 donors/group/experiment (left). Representative flow cytometry plots are gated on CD4+ 
T cells. (B) Following 96 h primary culture, LN cells were washed and restimulatedwith T-cell-
depleted syngeneic splenocytes pulsedwithMOG35–55. Supernatants collected 24 and 48 h later 
were analyzed by ELISA. Data are shown as mean + SEM of three samples from three 
independent experiments. (C) LN cells from primed mice were cultured for 96 h in the presence of 
MOG35–55 and Th17 polarizing factors after which they were rested in the absence of antigen or 
recombinant cytokines for an additional 96 h. They were then washed and restimulated with T-
cell-depleted splenocytes and MOG35–55. Cells were harvested 24 h later for intracellular 
staining followed by flow cytometry. Representative flow cytometry plots are gated on CD4+ T 
cells. (D) Supernatants from cells cultured for 96 h as in (A) were analyzed by the Luminex 
protein assay. Data are shown as mean + SEM of two samples from two experiments. (E) 
CFSE dilution (top) and activation status (bottom) of cells cultured as in (C). Cells were stained 
with CFSE prior to rechallenge with MOG35–55 (solid line) or media alone (shaded) and 
analyzed by flow cytometry 6 days later. Activation marker expression was assessed 24 h after 
rechallenge. Histograms are gated on CD4+ T cells. *** p < 0.001; ** p < 0.01; * p < 0.05 
compared to WT controls, unpaired two-tailed Student’s t-test. 
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We next compared the stability of MOG-primed, IL-23 polarized T-bet-/- and WT 
CD4+ CD45.2+ T cells in vivo following transfer into naïve CD45.1 congenic 
hosts.  Spleens harvested from the recipients of T-bet-/- donor cells contained a 
higher frequency of MOG35-55-specific IL-17 producers and a lower frequency of 
MOG35-55-specific IFN-γ producers than spleens from recipients of WT donor 
cells (Fig. 3A). These stable T-bet-/- Th17 cells induced EAE in 85-90% of hosts, 
although disease severity was reduced compared with recipients of WT cells 
(Fig. 3B).  IL-23 polarized T-bet-/- Th17 cells did not express FoxP3 and did not 
mitigate EAE severity when co-transferred with WT Th17 effectors (data not 
shown). 
 
FACS analysis of spinal cord mononuclear cells at peak disease indicated that 
the majority of infiltrating CD45.2+ T-bet-/- donor cells were IL-17+IFN-γ-, while the 
majority of infiltrating CD45.2+ WT donor cells were IL-17-IFN-γ+ (Fig. 3C). 
 
Tbet-/- Th17 cells transfer EAE to hosts lacking endogenous B or T lymphocytes 
Although T-bet-/- donor cells were enriched for the CD4+ T-cell subset prior to 
transfer, we entertained the possibility that immunocompetent host T cells had 
been activated by contaminating donor APCs bearing MOG35-55/ class II 
complexes.  Therefore, we repeated the adoptive transfer experiments using 
RAG2-/- recipients.  Consistent with the results obtained in immunocompetent 
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hosts, RAG2-/- mice were susceptible to disease induced by IL-23 polarized T-
bet-/- donor cells (Fig 3D).  At peak disease, a very high percent of the T-bet-/- 
cells that had accumulated in the CNS of RAG2-/- recipients were IL-17+IFN-γ- 
(Fig. 3E and F).  Similarly, the frequency of IL-17+IFN- γ- T-bet-/- cells was 
significantly higher than that of WT donor Th17 cells in the spleen (Fig. 3F). IFN-
γ single-producing T-bet-/- cells were virtually undetectable either in the spleen or 
the CNS.  In contrast, IL-17-IFN- γ + cells were more numerous than IL-17+IFN- γ - 
cells among the WT donor population in both the periphery and the CNS. 
Spleens of RAG2-/- mice that received T-bet-/- donor cells were disproportionately 
enlarged, primarily due to a local expansion of myeloid cells (Fig 3G, right panel).  
There was no difference in the absolute numbers of CD4+CD3+ T cells, 
granulocytes or monocytes infiltrating the spinal cords of T-bet-/- or WT hosts (Fig 
3G, left panel). 
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Figure 3.3. IL-23 polarized T-bet−/− Th17 cells are encephalitogenic (legend on next page). 
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Figure 3.3. IL-23 polarized T-bet−/− Th17 cells are encephalitogenic. (A–C) IL-23 polarized T-
bet−/− and WT CD4+ T cells were adoptively transferred into naïve CD45.1 congenic hosts (5 × 
106 CD4+ T cells/recipient). (A) Splenocytes harvested from hosts at peak disease were 
subjected to IL-17 and IFN-γ ELISpot assays. Background spots (detected in wells that were not 
pulsed with antigen) were subtracted to generate the Ag-specific data shown. (B) Adoptive 
transfer recipients of WT (closed symbols) or T-bet−/− (open symbols) MOG-reactive Th17 cells 
were rated on a daily basis for degree of neurological disability. The data shown are from one 
experiment with 4–6 mice/group representative of three performed. (C) CNS mononuclear cells 
obtained at peak disease were analyzed for intracellular cytokine expression by flow cytometry 
following stimulation with PMA and ionomycin for 6 h. Representative flow cytometry plots are 
gated on CD4+CD45.2+ donor T cells. (D–G) WT (closed symbols) or T-bet−/− 
(open symbols) Th17 cells were transferred into na¨ıve RAG2−/− hosts (5 × 106 CD4+ T 
cells/recipient). (D) Recipients were monitored on a daily basis and scored for degree of 
neurological disability. (E, F, G) CNS mononuclear cells and (F, G) splenocytes were harvested 
at peak disease and analyzed for (E, F) intracellular cytokine expression and (G) surface marker 
expression by flow cytometry. Representative flow cytometry plots for intracellular cytokine 
expression are gated on CD4+ donor T cells. Monocytes were defined as CD11bposLy6Cint-
hiLy6Gneg. Granulocytes were defined as  
cD11bposLy6CintLy6Gpos. (D, F, G) Data are shown as mean + SEM of four mice per group 
from one experiment representative of three performed. *** p < 0.001; ** p < 0.01; * p < 0.05 
compared to WT controls, unpaired two-tailed Student’s t-test.  
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Discussion 
 
 
MS is a heterogeneous disease characterized by diversity in both the clinical 
course and in responsiveness to individual therapeutic agents.  At present, no 
biomarkers have been identified that can guide the selection of an optimal 
disease modifying regimen.  Strategies to manage MS are complicated by the 
observation that distinct myelin-reactive Th-cell subsets can induce inflammatory 
demyelination via independent cellular and molecular pathways [1]. Therefore it 
is not surprising that signature Th1 and Th17 cytokines are dispensable for the 
manifestation of EAE [3-5].  The identification of a molecule that is critical for 
encephalitogenicity, irrespective of Th effector phenotype, would serve as an 
ideal therapeutic target. The transcription factor T-bet has been proposed as a 
candidate therapeutic target in MS, based on its non-redundant roles in Th1 
differentiation and in Th17 plasticity.  However, in the current study we show that 
IL-23 polarized myelin-reactive Th17 cells can mediate autoimmune 
demyelination without expressing T-bet or converting into Th1 (“ex-Th17”) cells. 
Consistent with our findings, Duhen et. al. [21] recently reported that T-bet 
deficiency confined to CD4+ T cells does not confer resistance against EAE 
induced by active immunization with MOG peptide emulsified in CFA. We found 
that stable T-bet-/- Th17 cells maintain the capacity to produce GM-CSF, and 
induce augmented production of CXCL2, each of which has been implicated in 
EAE pathogenesis [15, 22-24].  In ongoing studies we are investigating whether 
compensatory upregulation of these factors drives the accumulation of myeloid 
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cells (Ly6G+ granulocytes in particular) in the spleens of the recipients of T-bet-/- 
Th17 donor cells. Engagement of alternative chemokine/cytokine 
pathways could underlie the preserved encephalitogenicity of myelin-reactive T-
bet-/- Th17 cells.  
 
We consistently found that MOG-specific T-bet-/- Th17 cells induce a milder 
course of EAE than their WT counterparts. This could be due to reduced 
production of the pro-inflammatory factor GM-CSF, as we observed in primary 
cultures of T-bet-/- and WT CD4+ T cells (Fig. 2A).  However, we detected similar 
frequencies of GM-CSF+ cells among T-bet-/- and WT donor cells harvested from 
the CNS and peripheral lymphoid tissues of adoptive transfer recipients with EAE 
(Fig. 3F and data not shown).  Furthermore, MOG-primed, Th17 polarized T-bet-/- 
and WT cells produce comparable amounts of GM-CSF upon secondary 
challenge (Supplementary Information Fig. 1).  The diminished potency of T-bet-/- 
donor cells could also be secondary to a failure to express adhesion molecules, 
such as P-selectin ligand, and chemokine receptors, such as CXCR3, that 
facilitate efficient CNS trafficking [25].  The delay in clinical onset that we 
observed following adoptive transfer of T-bet-/- effectors into RAG2-/- hosts (Fig.1 
D) is consistent with that hypothesis. Finally, our experiments revealed 
differences in the composition of myeloid cells that were mobilized and recruited 
by T-bet-/- versus WT effector cells (Fig. 3G and data not shown) which could be 
responsible for differences in EAE severity.  Each of the above possibilities is 
currently under investigation in our laboratory. 
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 In conclusion, the current study contributes to a growing body of data that 
demonstrates that multiple parallel immunopathogenic pathways can potentiate 
autoimmune neuroinflammation, and it suggests that disease modifying therapies 
might need to be customized based on immune profiling.  
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CHAPTER IV 
 
Diminished Potency of T-bet-Deficient Th17 Cells Suggests Impaired 
Homing to Sites of Inflammation 
 
Introduction 	  
As previously mentioned, T-bet is known to be critical for the transcriptional 
programming of Th1 cells, and recently several groups have raised questions 
about its possible contribution to Th17 development, especially during EAE. IL-23 
is critical for Th17 but not Th1 cell encephalitogenicity [1-3]. Several groups have 
also shown that IL-23 polarization promotes T-bet expression by Th17 cells, 
which thereby promotes their conversion to exTh17 cells [1, 3, 4].  This may 
suggest that IL-23- and T-bet-driven plasticity is a critical feature of 
encephalitogenic Th17 cells. Indeed, early studies determined that T-bet-
deficient mice are relatively resistant to disease following active immunization [5]. 
However, recent data, including published research presented in this 
dissertation, have demonstrated T-bet expression and Th17 plasticity are not 
absolutely required for the acquisition of encephalitogenicity by Th17 cells [6-9].  
 
We demonstrated that T-bet expression and Th17 cell plasticity are not critical for 
Th17 encephalitogenicity. However T-bet deficiency attenuates the potency of IL-
23 polarized Th17 cells. Hence, following transfer into Rag2-/- and wild-type mice, 
IL-23-polarized T-bet-deficient CD4+ cells were less potent at inducing EAE than 
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their wild-type counterparts. We hypothesized that the diminished potency of T-
bet-/- Th17 cells could be a result of the following possibilities: T-bet-/- Th17 cells 
were not proliferating or surviving appropriately; T-bet-/- Th17 cells were not 
promoting innate and resident cell effector function in the CNS or elsewhere; T-
bet-/- Th17 cells became regulatory or suppressive or promote a suppressive 
environment; or T-bet-/- Th17 cells became trapped somewhere outside of the 
CNS and could not effectively induce disease. 
 
With regard to the role of T-bet in proper CD4+ T cell homing, the role of T-bet 
has been previously described in the expression of chemokine and integrin 
expression on Th1 cells. T-bet deficient NK and Th1 cells have reduced 
expression of the sphingosine-1-phosphate receptor 5 (S1P15), which promotes 
egress from lymph nodes [10]. T-bet-deficient Th1 cells also demonstrate 
reduced binding to P-selectin by regulating the post-translational modifications of 
P-selectin ligand [11]. T-bet also regulates the expression of CXCR3, a 
chemokine receptor which binds CXCL9, CXCL10, and CXCL11, which are 
expressed in the CNS of mice with EAE and MS patients [12-14]. Though some 
groups have proposed that diminished CXCR3 expression explains the reduction 
in EAE severity in T-bet-deficient CD4+ Th1 cells, data from our lab has 
suggested that CXCR3 is not critical for, nor does it promote, Th1 or Th17 
trafficking to the CNS during EAE in wild-type mice [7, 15]. 
 
	  79	  	  
To investigate the factors of T-bet-deficient Th17 cells which promote their 
potency, we developed a co-transfer model of EAE induction. We primed wild-
type and T-bet-/- mice and polarized lymph node cells with IL-23. We then 
transferred cells into RAG2-/- hosts. RAG2-/- mice received either wild-type cells 
alone, T-bet-/- cell alone, or equal numbers of wild-type and T-bet-/- cells. We 
demonstrate that T-bet-deficient Th17 cells accumulated less in the CNS but not 
the periphery relative to wild-type Th17 cells, though their proliferation and 
survival appears to be similar. We conclude that several trafficking molecules are 
significantly altered in T-bet-deficient Th17 cells relative to WT in the same 
environment. This suggests that the defects seen in T-bet-deficient Th17 cells 
are a cell-intrinsic result of impaired trafficking. 
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Materials and Methods 
 
Mice and EAE Induction: C57Bl/6 (CD45.1+) mice (B6.SJL-Ptprca Pepcb/BoyJ) 
were purchased from The Jackson Laboratory and used as wild-type controls in 
co-transfer experiments. T-bet-/- mice were bred and maintained at the 
University of Michigan under specific pathogen-free conditions as previously 
described. Wild-type (CD45.1+) and T-bet-/- mice were immunized and lymph 
node cells were polarized in the presence of IL-23 and antigen. Following 
polarization, 2x106 CD4+ wild-type and/or 2x106 T-bet-/- cells were transferred 
into RAG2-/- hosts. Mice were monitored daily for signs of disease. 
Flow Cytometry: At peak EAE, CNS, spleen, blood cells were harvested as 
described. Cells were stained with fluorescently labeled antibodies specific for 
the indicated antigens. For in vivo  proliferation analysis, mice were treated with 
1mg BrdU. After 14-16 hours, BrdU incorporation was measured using FITC 
BrdU Flow Kit (BD Biosciences). Apotosis was measured using the Annexin  V 
Staining Kit (ebioscience).  
Data analysis and Statistics: Flow cytometry data was analyzed with FlowJo 
software (Treestar). Statistics were analyzed using GraphPad Prism Software 
(GraphPad Software) and p-values were determined using a t test. 
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Results 
 
We have previously demonstrated that following polarization with IL-23, 
transferred antigen-specific T-bet-/- Th17 cells are stable in the CNS and induce a 
less severe disease in wild-type and RAG2-/- hosts [8]. To investigate the 
mechanism by which T-bet promotes Th17 cell encephalitogenicity, we 
compared disease severity in RAG2-/- wild-type, T-bet-/-, or co-transfer recipients.  
Wild-type donor cells were from C57Bl/6 mice that express CD45.1 to 
differentiate them from T-bet-/- CD45.2 cells. Mice that received wild-type cells 
alone developed severe EAE while those that received T-bet-/- cells alone 
developed a delayed and and milder disease course, as previously 
demonstrated. Mice that received both wild-type and T-bet-/- cells developed 
EAE with a similar disease course to those mice that received wild-type cells 
(figure 4.1). T-bet-/- Th17 did not suppress EAE either by action of T-bet-/- Th17 
cells themselves of the environment they promote (figure 4.1).	  	  
 
We compared the migration, survival, and migration properties of wild-type and 
T-bet-/- CD4+ T cells following adoptive transfer model. Mice were sacrificed 
either following onset of EAE in recipients of wild-type cells (day 6-10 post-
transfer) or following onset of EAE in recipients of T-bet-/- cells (day 11-14 post-
transfer). We tracked transferred cells throughout the host using markers for 
CD4+ T cells and wild-type (CD45.1) and T-bet-/- (CD45.2) donor cells. 
Recipients of wild-type cells did not typically survive long enough to be examined  
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Figure 4.1. Co-transfer of T-bet-/- Th17 cells with wild-type (WT) Th17 cells does not 
suppress or delay WT-mediated disease. Wild-type (WT) or T-bet-/- mice were immunized with 
MOG35-55 and complete Freund’s adjuvant (CFA). 10-14 days later, lymph node cells were 
recovered and polarized in the presence of antigen, rIL-23, rIL-1α, anti-IFN-γ (XMG1.2) and anti-
IL-4 (A11B11). After 4 days, 2x106 CD4+ cells were transferred into RAG2-/- hosts. Mice were 
monitored daily for signs of EAE 
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at the later time point.  Co-transfer recipients and recipients of T-bet-/- Th17 cells 
alone were taken at both time points if possible. Following disease onset, 
infiltrating cells from the CNS were recovered and proportions and absolute 
numbers of CD45.1+ and CD45.2+ cells were analyzed. Recipients of both wild-
type and T-bet-/- cells had typically half as many T-bet-/- CD4+ cells in the brain 
and spinal cord as wild-type cells (Figure 4.2a and b). Interestingly, those 
recipients had similar or higher proportions and numbers of T-bet-/- CD4+ cells in 
the spleen. At later time points, when recipients of T-bet-/- cells had developed 
disease, a similar phenomenon was observed, indicating that once WT CD4+ 
cells had infiltrated the CNS, they would continue to outcompete T-bet-/- CD4+ 
cells, and T-bet-/- cells were not simply delayed in their accumulation in the CNS 
(Figure 4.2a, b). 	  
The difference seen between the frequency of wild-type and T-bet-/- CD4+ T cell 
accumulation in the CNS, but not the periphery, could be explained by 
differences in proliferation or apoptosis rates of T-bet-/- CD4+ T cells. We 
previously demonstrated that following rest and rechallenge in vitro, T-bet-/- CD4+ 
Th17 cells proliferated more slowly in response to antigen [8]. However, in vivo 
BrdU incorporation studies demonstrated proliferation rates were similar between 
wild-type and T-bet-/- cells in the CNS following disease onset (figure 4.3a). Next, 
apoptosis rates were measured using AnnexinV staining of cells from the CNS. 
Similar frequencies of AnnexinV+ cells were seen in wild-type and T-bet-/- CD4+ 
T cells in the CNS (figure 4.3b). 
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Figure 4.2. T-bet-/- CD4+ cells accumulate less in the CNS, but not the periphery, relative to 
wild-type CD4+ cells when placed in the same host. Following disease onset in RAG2-/- 
recipients of wild-type and/or T-bet-/- CD4+ T cells, spinal cord mononuclear cells and spleens 
were recovered and analyzed for frequency of wild-type or T-bet-/- CD4+ cells. A) Representative 
dot plots indicating gating scheme and typical results from spinal cord (top) and spleen. B) Bar 
graph of combined data. WT Peak indicates tissue harvested at early time point, T-bet-/- Peak 
indicates tissue harvested at later time point. 
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Figure 4.3. T-bet-/- Th17 cells have no defect in proliferation or survival.   RAG2-/- recipients 
of wild-type, T-bet-/-, or wild-type and T-bet-/-  (Co-transfer) Th17 cells were harvested at peak 
disease. Cells were isolated from brains, spinal cords, and spleens. A) BrdU incorporation was 
measured to assess proliferation across tissues. Data shown is graphed on wild-type or T-bet-/- 
donor CD4+ T cells. B) AnnexinV staining was measured to assess apoptosis across tissues. 
Data shown is graphed on wild-type or T-bet-/- donor CD4+ T cells. 
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In the absence of differences in survival or proliferation, we measured trafficking 
cytokine differences. As previously mentioned, several studies have described 
altered homing patterns in T-bet-deficient CD4+ T cells. Typically, these studies 
focused on IL-12-polarized Th1 cells to elucidate the mechanisms in which T-bet 
conferred Th1 function [8, 10, 11]. However, more recent data, including our own 
observations, have described the role of T-bet following IL-23 polarization, thus 	  
its role of controlling homing and trafficking in Th17 cells is worth revisiting [3, 7-
9]. Furthermore, since T-bet-deficient Th17 cells are considered to be highly 
polarized Th17 cells as they produce high, sustained levels of IL-17, it is possible 
homing molecules associated with Th17 cells are highly expressed on T-bet-/- 
Th17 cells. Several integrins, chemokines, and their receptors have been 
reported to be preferentially upregulated during either Th1 or Th17 responses. If 
the acquisition of Th1-like properties via Th17 cell plasticity involves the 
upregulation of Th1-associated trafficking molecules, perhaps the stability 
associated with T-bet-deficient Th17 cells also inhibits that upregulation. To 
investigate this, we measured the expression of chemokine receptors, integrins, 
and other molecules associated with trafficking of cells to various sites of 
inflammation within our co-transfer model. In the spinal cord at peak disease, we 
found that transferred T-bet-/- CD4+ T cells expressed significantly higher levels 
of CCR6, α4β7, α4β1, and CD127 (IL-7Rα). Data was similar in the spleen, 
though T-bet-/- cells in the spleen expressed significantly less CXCR3. CCR6 
has been shown to be critical for Th17 cell homing to the CNS and its ligands  
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Figure 4.4. T-bet-/- Th17 cells have altered homing molecule expression in the setting of 
inflammation. Wild-type and T-bet-/- Th17 cells were co-transferred into RAG2-/- hosts. At peak 
disease, cells from spinal cord (A) and spleen (B) were isolated and analyzed for homing 
molecules using FACS
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CCL19 and CCL20 are expressed in the CNS during EAE [16-18], The integrin 
α4β7 binds the gut-associated ligand MadCAM-1. α4β1, alternatively, was 
demonstrated to promote Th1 cell entry into the spinal cord during EAE and Th17 
cells are thought to traffic to the CNS independently of the α4 integrin [19, 20]. IL-
7Rα binds IL-7 and is associated with susceptibility to multiple sclerosis and has 
been shown to be a survival factor for Th17 cells [21]. We saw no difference in 
expression of the gut-homing chemokine receptor CCR9 between wild-type and 
T-bet-/- Th17 cells, nor did we see differences in S1P1 receptor expression or p-
selectin binding (data not shown). These data suggest that T-bet may play a role 
in Th17 cell homing, similar or related to its published role in Th17 cell homing, 
and in the absence of T-bet, Th17 cells have altered trafficking patterns to sites 
of inflammation. 
 
While we observed differences in chemokine receptor and adhesion molecule 
expression between transferred wild-type and T-bet-/- Th17 cells, we investigated 
other mechanisms that could lead to the reduced potency of T-bet-/-  cells. We 
considered the possibility that T-bet-/-  Th17 cells acquired a regulatory or 
suppressive phenotype or promoted the expansion of host cells which could 
suppress autoimmunity.  As previously mentioned, mice which received both 
wild-type and T-bet-/-  T cells developed a similar disease course to that seen in 
mice which received wild-type cells alone. This suggests that T-bet-/-   cells could 
not suppress the encephalitogenicity of wild-type cells and did not acquire a 
regulatory phenotype. We also did not observe FoxP3 expression by T-bet-/- 
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cells.  Furthermore, as previously mentioned in chapter III, RAG2-/- mice that 
received T-bet-/-  T cells developed splenomegaly relative to RAG2-/- mice that 
received wild-type cells. This was a result of a significant Ly6c+Ly6g+ myeloid 
cell accumulation. These myeloid cells could be the recently described myeloid-
derived suppressor cells, which are typically studied in the setting of tumor 
immunity [22]. However, Ly6c+Ly6g+ myeloid cell numbers in spleens of co-
transfer mice were similar to those that received wild-type cells alone (figure 4.5). 
Wild-type cells were dominant in promoting disease and were not controlled by 
those myeloid cells. In the absence of those cells in the co-transfer model, we 
observed the described paucity of T-bet-/- cells in the CNS, which is the most 
likely explanation for the reduced disease severity seen in RAG2-/- recipients of 
T-bet-/- cells. This observation did not eliminate the possibility that T-bet-/- CD4+ T 
cells did elicit myeloid-derived suppressor cells when transferred into RAG2-/- 
mice, and future studies will be to investigate the role of myeloid cell 
accumulation in this model.   
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Figure 4.5.  Recipients of both wild-type and T-bet-/- Th17 cells did not develop myeloid cell 
accumulation in the spleens of RAG2-/- hosts. Spleen cells were recovered from RAG2-/- 
recipients of wild-type, wild-type and T-bet-/- cells, or T-bet-/- alone at an early and late time point. 
Monocytes were gated on CD11b+Ly6c+Ly6g- cells while granulocytes are gated on 
CD11b+Ly6c+Ly6g+ cells. (*p<.05) 
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Discussion 
 
While several groups have determined a critical role for T-bet in Th1-associated 
function and trafficking, newer data have described the importance for T-bet in 
Th17 plasticity and IL-23 polarization. We previously published that T-bet 
deficient Th17 cells induce EAE in RAG2-/- and wild-type hosts, however with 
reduced severity and delayed onset. We determined using co-transfer models of 
disease that in T-bet-/- Th17 cells accumulate less in the CNS but to similar levels 
in the periphery. We determined this was not a result of deficits in survival or 
proliferation, nor the promotion of an anti-inflammatory or suppressive 
environment, and was likely a defect in CD4+ T cell trafficking to the CNS.  
 
Though our results were inconclusive as to which particular receptors were 
critical to the defects in T-bet-/- homing, we could determine that the defect was 
intrinsic to T-bet deficient Th17 cells rather than differences in host responses 
between wild-type and T-bet-/- Th17-mediated adoptive transfer models of EAE. 
The advantage of using a co-transfer model was that wild-type and T-bet-
deficient CD4+ T cells could be analyzed within the same environment of 
inflammation following EAE onset, eliminating the possibility that host 
proinflammatory cells and molecules were not properly activated in the presence 
of T-bet-/- CD4+ T cells.  
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In future experiments, we hope to better clarify the particular homing receptors 
that are regulated by T-bet to promote proper Th17 cell trafficking.  We will gain a 
better understanding of the significance of the upregulation of certain gut-homing 
molecules in T-bet-/- Th17 cells by measuring transferred T-bet-/- accumulation in 
the gut. Furthermore, we appreciate the possibility that pleiotropic functions of T-
bet as a transcription factor may lead to several dysregulated transcriptional 
networks in its absence, leading to a large number of possible solutions to the 
diminished potency of T-bet-/- cells in this model. Using this co-transfer adoptive 
transfer model will promote understanding of the effect of T-bet deficiency in 
Th17 cells within the same setting of inflammation as functional wild-type cells. 
Lastly, these data have reinforced the understanding that T-bet, though critical 
for Th1 differentiation, is certainly involved in IL-23-driven Th17 cell immunology. 
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CHAPTER V 
 
 
DISCUSSION 
 
 
Based on previously published literature, the contributions of Th1 cells, stable 
Th17 cells, and exTh17 cells to disease development in the adoptive transfer 
model of EAE were unclear. The research described in this dissertation 
attempted to answer the following questions:  
• Is IL-23 required for Th1 CD4+ T cell encephalitogenicity?  
• Is plasticity a critical feature of Th17 cell encephalitogenicity?  
• Do stable IL-23-polarized cells have fundamentally different properties than 
plastic Th17 cells? 
The answers to these questions, described below, augment the current model of 
adoptive transfer EAE. This updated model, its analogous active immunization 
model of EAE, and chapters in which specific features have been discussed, as 
well as a classical model for T cell polarization and remaining questions, are 
illustrated in figure 5.1. Table 5.1 demonstrates the notable features of disease 
driven by each lineage.  
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Figure 5.1.  IL-12 and IL-23 in the development of encephalitogenic CD4+ T cell lineages 
during EAE. A) The role of IL-12 and IL-23 in classical pathways of Th1, Th17, and exTh17 
development and the critical and dispensable elements in B) the active immunization model of 
EAE and C) the adoptive transfer model of EAE. Several conclusions illustrated here were drawn 
from data published in this dissertation. 
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 Properties Encephalitogenic 
Potential 
Th1 Enriched monocyte recruitment, accumulation 
Does not require IL-23 
++ 
Th17 
(stable) 
Enriched neutrophil recruitment, accumulation 
Does not require IL-12 
Does not require T-bet 
Less efficient at inducing EAE following adoptive 
transfer than Th1 or exTh17 cells 
+ 
exTh17 More efficient than stable Th17 cells in homing to 
the CNS 
More efficient than stable Th17 cells in inducing 
EAE 
IL-12 signaling by host promotes exTh17 
development 
++ 
 
 
Table 5.1. Properties of EAE induced by Th1 cells, stable Th17 cells, and exTh17 cells.
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IL-12 polarized Th1 cells do not require IL-23 for encephalitogenicity 
In Chapter II, we showed that IL-12-polarized Th1 cells induce EAE 
independently of IL-23. This is a novel finding that contradicts the current dogma 
that IL-23 exposure is universally critical for CD4+ T cell encephalitogenicity. 
Furthermore, IL-23-independent Th1 cells induced disease more efficiently than 
IL-12-independent Th17 cells. Each lineage was highly polarized as defined by 
IFN-γ and IL-17 cytokine expression patterns prior to transfer and maintained 
those cytokine profiles following disease onset. IL-23-independent Th1 transfers 
elicited a monocyte-rich pattern of infiltration compared to IL-12-independent 
Th17 transfers, and a distinct global profile of cytokine and chemokine 
production. Using serum collected from MS patients, we used relative IL-12 and 
IL-23 levels to define MS patients groups. IL-12-skewed, IL-23-skewed, and 
unskewed patients formed three distinct groups in ordination space based on the 
expression levels of several cytokine and chemokines. 
 
These data suggest that IL-12 and IL-23 drive distinct disease mechanisms in 
EAE and that adoptive transfer models can be used to determine features of 
those mechanisms. Furthermore, relative IL-12 and IL-23 expression, as 
opposed to IFN-γ and IL-17 expression, may be a better way to define Th1- or 
Th17-biased MS patient groups since the expression of those so-called signature 
cytokines is more mutable than the expression of innate polarizing cytokines. 
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Future studies using IL-12-independent and IL-23-independent EAE models will 
measure properties of highly polarized, encephalitogenic Th1 and Th17 cells 
following transfer, including survival, proliferation, and trafficking. According to 
the literature, IL-23 signaling drives both the plasticity and encephalitogenicity of 
Th17 cells. Hence, it was surprising to find that donor IL-23-polarized Th17 cells 
fail to convert to ex-Th17 cells in IL-12 deficient hosts. Furthermore, Th17 
polarized myelin-specific T cells were less potent in IL-12 deficient than WT 
hosts. Preliminary data have demonstrated that, following transfer and EAE 
onset, IL-12Rβ2-/- Th17 cells sometimes “disappear” and cannot be detected in 
the CNS or periphery. This, along with data in this dissertation that demonstrate 
that transferred IL-12Rβ2-/- Th17 cells are stable, may suggest that IL-12 
signaling promotes the survival of bona fide Th17 cells during the effector phase 
of EAE. Elucidating the mechanisms by which IL-12R promotes Th17 cell 
survival and plasticity would lead to novel findings that would add new 
perspectives on the distinction between Th1 and Th17 cells. Other future studies 
include examining the relevance of various effector cytokines and cell 
populations in IL-12 versus IL-23-driven disease. We also hope to determine the 
significance of the enrichment of monocytes and possible reduction in neutrophils 
in the CNS of mice with Th1-driven EAE versus Th17-driven EAE. While transfer 
of IL-23-independent Th1 cells into CCR2-/- hosts, which have impaired monocyte 
trafficking, resulted in reduced disease relative to wild-type hosts, we have not 
demonstrated that phenomenon is specific for highly polarized Th1-mediated 
disease but not Th17-mediated disease. Similarly, it is unclear if IL-12-
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independent Th17-mediated disease, but not IL-23-independent Th1-mediated 
disease, is dependent on neutrophil recruitment to the CNS. 
 
Currently, data and patient samples are available that were not used in the 
analyses published here, including MRI activity and clinical disease severity. 
Adding more parameters and patients to the human datasets may better refine 
our hypothesis that relative IL-12 and IL-23 expression defines distinct patient 
groups. Furthermore, if other published open-access MS patient studies that are 
available include patient IL-12 or IL-23 expression in any context, we can 
consider those data to determine if our conclusions hold across institutions and 
populations. 
 
Data generated from MS patient serum averaged over 12 blood draws per 
patient at various stages of disease (and a very small number of patients) could 
be considered a poor comparison to data from brain and spinal cord 
homogenates from mice at the peak of EAE. Furthermore, the adoptive transfer 
model of EAE involves a great deal of manipulation in vitro. Active immunization 
eliminates the variables associated with ex vivo culture conditions. Studies with 
genetically engineered C57BL/6 mice indicate that EAE induced by active 
immunization requires IL-23-polarized Th17 cells and not Th1 cells for clinical 
manifestation. It is unclear why IL-12 is insufficient to promote disease in actively 
immunized IL-23-deficient mice. The adjuvant in CFA used for active 
immunization, Mycobacterium tuberculosis, is a potent inducer of IL-12. One can 
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speculate that in C57BL/6 mice, myelin antigen-specific CD4+ T cells must traffic 
through a region where a high level of IL-23 is produced prior to activation or 
initiation of effector function in the CNS. For example, high levels of IL-23 are 
produced in the gut, and Th17 cells are found at a high frequency in gut-
associated lymphoid tissue (GALT). It is possible that in IL-23-deficient mice, 
myelin antigen-specific CD4+ T cells traffic through the GALT but are not 
secondarily activated or licensed by IL-23 to become fully encephalitogenic. 
Nevertheless, the adoptive transfer data shown here demonstrate the ability of 
IL-12 to circumvent the requirement for IL-23 for the acquisition of 
encephalitogenicity in vitro. The results of our human, as well as murine, studies 
support the hypotheses that IL-12 and IL-23 drive distinct CNS-targeted 
autoimmune diseases and suggest that these pathways could be differentially 
targeted. 
 
Th17 cell plasticity is not required to induce EAE 
In Chapter III, we demonstrated that IL-23-polarized T-bet-/- Th17 cells have 
characteristics of stable, highly polarized Th17 cells. Following adoptive transfer, 
T-bet-/- Th17 cells induced EAE in wild-type and RAG2-/- hosts. Furthermore, 
following transfer, T-bet-/- Th17 cell populations remained high IL-17-producers 
and produced little IFN-γ, while wild-type Th17 cell populations were 
predominantly IFN-γ-producers and produced little IL-17. Therefore, these data 
reinforce previous findings that T-bet is required for Th17 cell plasticity, and also 
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demonstrate the novel finding that the feature of plasticity is not absolutely 
required for IL-23-polarized cells to become encephalitogenic.  
 
Stable Th17 cells exhibit unique homing properties 
While T-bet-/- Th17 cells could induce EAE, disease was mild and delayed 
relative to wild-type controls. Chapter IV pursued those data reported in Chapter 
III and investigated the mechanisms of the reduced potency of T-bet-/- Th17 cells. 
Using co-transfer models where IL-23 polarized wild-type and T-bet-/- CD4+ T 
were injected into the same RAG2-/- host, we determined that T-bet-/- cells 
accumulate less in the CNS, but not in the periphery, relative to wild-type cells. 
This did not appear to be a result of defective proliferation or elevated apoptosis 
in T-bet-/- cells. However, the transferred T-bet-/- CD4+ cells expressed different 
homing molecules than WT cells.  Specifically, T-bet-/- cells expressed CCR6, 
and α4β7 while WT cells expressed CXCR3. 
 
Like Chapter II, Chapters III and IV have broad implications in Th17 cell biology 
and the properties that promote Th17 cell encephalitogenicity. The data 
demonstrate that Th17 cell plasticity is dispensable for Th17 cell function in EAE, 
but it may promote Th17 cell potency. Previous reports have demonstrated that 
though T-bet is considered to be a Th1-associated factor, it is upregulated in 
Th17 cells following IL-23 exposure and during EAE, even in the absence of IFN-
γ and IL-12 [1]. Our data suggest that T-bet is not absolutely required for 
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autoimmune Th17 cell function but does influence T cell trafficking and, 
consequently, the efficiency with which effector cells infiltrate their target organ.   
 
Future studies will examine the trafficking properties of T-bet-/- Th17 cells in 
detail. Based on the integrins and receptors that were upregulated on Th17 cells, 
it is possible that these cells preferentially home to non-CNS tissues, including 
gut-associated lymphoid tissue. The ligand for α4β7, MadCAM-1, is expressed 
highly in gut associated tissues. We hypothesize that administration of α4β7- and 
MadCAM-1 blocking reagents to the adoptive transfer recipients of T-bet-/- Th17 
cells will result in a redistribution of donor cells such that less accumulate in the 
GALT and more in the CNS.  If that is the case those blocking agents will 
paradoxically cause disease exacerbation in recipients of T-bet-/- Th17 cells.  
 
Questions also remain regarding the relevance of the Ly6G+ myeloid cells that 
expand in the spleens of RAG2-/- hosts following transfer of wild-type, but not T-
bet-/- Th17 cells. It is possible those Ly6G+ cells are suppressive and contribute 
to the reduced severity of EAE seen in recipients of T-bet-/- Th17 cells. In tumor 
models, Ly6g+ myeloid cells, or myeloid-derived suppressor cells (MDSC) have a 
suppressive effect on T cell responses to promote tumor survival [2]. MDSC have 
been previously described in EAE, though their identification and veracity as 
CD4+ T cell suppressors in vivo is unclear [3, 4]. Comparing these cells to 
previously described myeloid-derived suppressor cells by measuring cell-surface 
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marker and cytokine expression, as well as functional T cell suppression assays, 
will help determine whether they are contributing to reduced disease.  
 
Several groups have published on the role of T-bet in efficient T cell trafficking, 
though most of those studies have been done in the context of IL-12-polarized 
Th1 cells or other cell lineages. T-bet controls CXCR3 expression in CD8+ cells, 
Th1 cells and regulatory T cells [5]. T-bet deficient cells also express less 
sphingosine-1-phosphate receptors 1 and 5 and P-selectin ligand [6, 7]. 
However, the role of T-bet in Th17 cell trafficking is largely unexamined. The data 
published here suggest that IL-23-polarized T-bet deficient T cells are 
reminiscent of highly polarized Th17 cells. Therefore it would be reasonable to 
predict that Th17-associated trafficking molecules, including α4β7, CCR6, and 
other gut-homing receptors are enriched on T-bet deficient IL-23-polarized cells. 
Furthermore, as T-bet is a pleiotropic transcription factor that regulates not just 
Th1 development but several other pathways, including the conversion of Th17 
cells to exTh17 cells, it would seem that the acquisition of the exTh17 profile via 
T-bet would include the altered expression of Th1-associated trafficking 
molecules. This would confirm the assumption that the conversion to an exTh17 
cell is not simply the upregulation of IFN-γ and downregulation of IL-17, but a 
shift in the entire expression profile of the Th17 cell. It would be interesting if this 
shift resulted in a “hybrid” of Th1 and Th17 cell trafficking profiles, contributing to 
the unique properties of exTh17 cells. 
 
	   105 
The role of Th17 cells, exTh17 cells, and Th1 cells in autoimmune disease 
 
Collectively, this dissertation describes the factors that are dispensable or 
required for the encephalitogenicity of Th1, Th17, or exTh17 cells, as well as 
distinct and overlapping properties of EAE induced by each of these subsets 
(Table 5.1). While these data clarify the contributions of exTh17 cells and IL-12 to 
EAE (and possibly MS), further questions remain and are listed in figure 5.1. 
Furthermore, the aforementioned questions regarding the relevance of EAE to 
MS and the artificial nature of the adoptive transfer model raises the possibility 
that our results are an artifact of culture conditions or specific for mouse models 
of neuroinflammation. Nonetheless, there is evidence that Th1, Th17, or exTh17 
play similar roles in other rodent models of autoimmunity and disease. Muranski 
et al. determined that tumor-specific Th17 cells could efficiently eliminate tumors 
following adoptive transfer. Not only did this absolutely require the ability for Th17 
cells to acquire exTh17 cell properties (including the expression of IFN-γ and T-
bet), but transferred Th1 cells were unable to eradicate tumors, suggesting a 
functional distinction between Th1 cells and exTh17 cells [8]. In fact, unlike data 
published in this dissertation, T-bet was absolutely required for Th17 cells to 
clear tumors, suggesting exTh17 cells are also functionally distinct from Th17 
cells in this model. This also suggests the presence and function of exTh17 cells 
in models outside of autoimmunity. In another example, adoptive transfer models 
of diabetes demonstrate that disease can be induced with Th1 cells, and to a 
lesser extent Th17 cells, but the upregulation of IFN-γ by those Th17 cells is 
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critical to their pathogenicity [9]. These data suggest that even in other mouse 
models, exTh17 cell development promotes or is critical to Th17 cell function, 
and exTh17 cell function is distinct from that of Th1 cells.  
 
T-bet-deficient Th17 cells and IL-12 signaling-deficient Th17 cells fail to 
upregulate IFN-γ following disease onset and induce disease less efficiently than 
either wild-type Th17 cells or IL-23-deficient Th1 cells. IL-12R expression is 
controlled by T-bet in a positive feedback loop following IFN-γ exposure, but T-
bet is also upregulated by T cells following IL-23 exposure. Furthermore, it has 
been demonstrated that T-bet is upregulated in CD4+ cells during EAE in even in 
mice deficient in IL-12- and IFN-γ signaling pathways [1]. T-bet should then be 
sufficiently upregulated by IL-23-polarized IL-12R-deficient Th17 cells transferred 
into wild-type hosts. However if that were the case, why are IL-12R-deficient 
Th17 cells stable? It is also curious that although actively immunized mice 
deficient in IL-12 signaling are susceptible to EAE, the IL-12p40-deficient 
transfers of IL-23-polarized cells were a great deal less efficient at inducing 
disease. Therefore, there are paradoxes that seem to link IL-12 to exTh17 
development and Th17 cell encephalitogenicity in vivo.  
 
The description of the exTh17 lineage has been fascinating because it blurs the 
lines between two functionally distinct CD4+ T cell subsets, whose function in 
several other disease models and human diseases depends on the signature 
cytokines they produce. IFN-γ production by CD4+ cells is critical for mice to 
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survive Listeria monocytogenes, Toxoplasma gondii infection, and Salmonella 
enterica [10]. Incidentally, Listeria infection is cleared in the absence of IL-23R 
signaling. IFN-γ is thought to mainly activate macrophages and promote MHCII 
expression, as well as its aforementioned role in the expression of CXCR3 and 
its ligands. IL-17A on the other hand, is critical for clearance of extracellular 
bacterial and fungal infections, including Klebsiella pneumoniae and Candida 
albicans, and is thought to promote activation and recruitment of neutrophils [11]. 
However, during EAE as well as collagen-induced arthritis, a rodent rheumatoid 
arthritis disease, IFN-γ expression not required for disease [12-15]. Not only does 
this observation promote the assumption that Th17 cells and not Th1 cells are 
the single critical mediators of EAE, it undermines the relevance of IFN-γ-
producing exTh17 cells. Indeed, in mice lacking IL-23R, Th17 cells develop, but 
are not encephalitogenic, and do not convert to exTh17s [10, 16]. However, it is 
important to consider that our lab has demonstrated that IL-23-polarized myelin-
specific T cells require IFN-γ and not IL-17 to promote EAE. Also, the shift in a 
transcriptional program induces a network of change, and while it is convenient 
to examine two informative cytokines, alterations of other critical factors could be 
overlooked. Further description and comparison of these three subsets will define 
those factors. Unfortunately, until those definitions arise, the relevance of bona 
fide exTh17 cells in human disease will be difficult to measure. Nonetheless, 
cells expressing both Rorc and T-bet, as well as IFN-γ and IL-17, have been 
recovered from patients with Crohn’s Disease; Th17 cells that are able to convert 
into Th1 and other CD4+ cell lineages ex vivo have been recovered from patients 
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with ulcerative colitis, graft versus host disease, and colon cancer [17, 18]. 
Furthermore, as mentioned previously, there have been reports on the presence 
of IFN-γ- and IL-17-producing T cells in the periphery and CNS of patients with 
active MS, and more recent reports have described IFN-γ-producing Th17 cells 
recovered from the periphery of patients with MS are able to cross a model of the 
blood brain barrier [19, 20]. These data suggest the existence of a population of 
Th17 cells with Th1-associated properties in human disease, and whether their 
relevance is similar to that seen in mouse models is yet to be determined. 
 
As previously discussed, MS is a highly heterogeneous disease and patients 
have variable responses to available disease modifying therapies. Overall, the 
data presented here suggest distinct molecular mechanisms for CNS-targeted 
autoimmune diseases in mouse and human. Though IL-12 and IL-23 expression 
and exTh17 development has been measured and controlled in these rodent 
studies to determine their pathogenicity independently of each other, it is 
certainly possible that those lineages have a common downstream mechanism of 
pathogenesis. Indeed, our research using the EAE model determined those both 
IL-12- and IL-23-driven diseases have similar clinical phenotypes, so the 
possibility that the two pathways converge to form a similar outcome would not 
be surprising.  If this were the case, treatment of MS could be uniform and 
relatively straightforward across patients. However, the differences in 
inflammatory cytokine production, T cell trafficking, myeloid cell recruitment to the 
CNS and in the periphery, patterns of infiltration, and overall potency of the Th 
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lineages suggest EAE--and likely MS--has several non-overlapping mechanisms 
that result in autoimmune disease.  MS risk is determined by genetic influences, 
infection, and environmental factors that could each promote distinct innate 
cytokine profiles. Thus, any of those factors could promote the induction of one 
pathway over another to induce disease. If a multi-pathway theory were true, 
treatment for MS would require the identification of dominating mechanisms 
within each patient using biomarkers, then targeting treatment toward those 
mechanisms. For example, it has been reported that accepted treatments for MS, 
including IFN-β, fingolimod, and dimethyl fumarate can suppress Th17 cell 
development and function [21-24]. Other groups have attempted to divide 
patients into responders and non-responders and determine IL-17 expression 
profiles, though with limited success [25]. Ultimately, stratifying patients based on 
distinct molecules or features is the appropriate strategy of determining whether 
those features are relevant for MS. 
 
In the adoptive transfer model of EAE, IL-12 and IL-23 can be mutually exclusive 
and exTh17 cell function is separate from Th1 and Th17 cell development. Using 
the models described, further clarification of each of those populations could lead 
to better understanding their roles in other mouse models, as well as in 
autoimmune disease in human populations. 
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